EU-RISK MANAGEMENT PLAN FOR XENPOZYME® (OLIPUDASE ALFA) 
Data Lock Point (DLP) 
RMP Version number 
Date of final sign-off 
31-OCT-2022 
Version 2.3 
06-NOV-2023 
 
 
 
 
 
 
 
 
 
Table 1 - RMP version to be assessed as part of this application  
Rationale for submitting an 
updated RMP 
The RMP has been updated to revise phase 2/3 clinical trial (DFI12712 ASCEND) 
final study report submission milestone and LTS13632 study milestone. 
Summary of significant 
changes in this RMP 
RMP: Risk Management Plan. 
The following modules and annexes have been updated: 
Cover page, Part I and Part III. 
Annexes 2 and 8. 
Table 2 - Other RMP versions under evaluation  
RMP Version number  
Submitted on  
Submitted within  
Not applicable 
RMP: Risk Management Plan. 
- 
- 
Table 3 - Details of the currently approved RMP  
Version number  
Version 2.2 
Approved with procedure 
EMEA/H/C/004850/II/0001/G 
Date of approval (opinion date) 
16-Mar-2023 
RMP: Risk Management Plan. 
Table 4 - QPPV name and signature  
QPPV name 
QPPV signature 
Electronic signature on file 
a  Deputy QPPV by delegation from Heike Schoepper, QPPV for Sanofi. 
QPPV: Qualified Person Responsible for Pharmacovigilance. 
 
 
TABLE OF CONTENT  
TABLE OF CONTENT .................................................................................................................................... 3 
LIST OF TABLES............................................................................................................................................ 5 
ABBREVIATIONS ........................................................................................................................................... 7 
RISK MANAGEMENT PLAN - PART I: PRODUCT (S) OVERVIEW ............................................................ 9 
RISK MANAGEMENT PLAN - PART II MODULE SI: EPIDEMIOLOGY OF THE INDICATION(S) 
AND TARGET POPULATION(S) .................................................................................................. 12 
RISK MANAGEMENT PLAN - PART II MODULE SII: NON-CLINICAL PART OF THE SAFETY 
SPECIFICATION ........................................................................................................................... 15 
RISK MANAGEMENT PLAN - PART II MODULE SIII: CLINICAL TRIAL EXPOSURE ............................. 20 
RISK MANAGEMENT PLAN - PART II MODULE SIV: POPULATIONS NOT STUDIED IN CLINICAL 
TRIALS .......................................................................................................................................... 34 
SIV.1 
SIV.2 
SIV.3 
EXCLUSION CRITERIA IN PIVOTAL CLINICAL STUDIES WITHIN THE DEVELOPMENT 
PROGRAMME ............................................................................................................................... 34 
LIMITATIONS TO DETECT ADVERSE REACTIONS IN CLINICAL TRIAL DEVELOPMENT 
PROGRAMMES ............................................................................................................................. 35 
LIMITATIONS IN RESPECT TO POPULATIONS TYPICALLY UNDER-REPRESENTED IN 
CLINICAL TRIAL DEVELOPMENT PROGRAMMES .................................................................... 35 
RISK MANAGEMENT PLAN - PART II MODULE SV: POST-AUTHORIZATION EXPERIENCE .............. 38 
RISK MANAGEMENT PLAN - PART II MODULE SVI: ADDITIONAL EU REQUIREMENTS FOR 
THE SAFETY SPECIFICATION .................................................................................................... 39 
SVI.1 
POTENTIAL FOR MISUSE FOR ILLEGAL PURPOSES .............................................................. 39 
RISK MANAGEMENT PLAN - PART II MODULE SVII: IDENTIFIED AND POTENTIAL RISKS............... 40 
SVII.1 
IDENTIFICATION OF SAFETY CONCERNS IN THE INITIAL RMP SUBMISSION ..................... 40 
SVII.1.1  Risks not considered important for inclusion in the list of safety concerns in the RMP ................. 41 
SVII.1.2  Risks considered important for inclusion in the list of safety concerns in the RMP ....................... 43 
SVII.2  NEW SAFETY CONCERNS AND RECLASSIFICATION WITH A SUBMISSION OF AN 
UPDATED RMP ............................................................................................................................. 45 
SVII.3  DETAILS OF IMPORTANT IDENTIFIED RISKS, IMPORTANT POTENTIAL RISKS, AND 
MISSING INFORMATION .............................................................................................................. 45 
 
 
 
SVII.3.1  Presentation of important identified risks and important potential risks ......................................... 46 
SVII.3.2  Presentation of the missing information ......................................................................................... 49 
RISK MANAGEMENT PLAN - PART II MODULE SVIII: SUMMARY OF THE SAFETY CONCERNS ...... 51 
RISK MANAGEMENT PLAN - PART III: PHARMACOVIGILANCE PLAN (INCLUDING 
POST-AUTHORIZATION SAFETY STUDIES) ............................................................................. 52 
III.1 
III.2 
III.3 
ROUTINE PHARMACOVIGILANCE ACTIVITIES ......................................................................... 52 
ADDITIONAL PHARMACOVIGILANCE ACTIVITIES .................................................................... 52 
SUMMARY TABLE OF ADDITIONAL PHARMACOVIGILANCE ACTIVITIES .............................. 54 
RISK MANAGEMENT PLAN PART IV: PLANS FOR POST-AUTHORIZATION EFFICACY STUDIES .... 57 
RISK MANAGEMENT PLAN - PART V: RISK MINIMIZATION MEASURES (INCLUDING 
EVALUATION OF THE EFFECTIVENESS OF RISK MINIMIZATION ACTIVITIES) ................... 58 
V.1 
V.2 
V.3 
ROUTINE RISK MINIMIZATION MEASURES .............................................................................. 58 
ADDITIONAL RISK MINIMIZATION MEASURES ......................................................................... 59 
SUMMARY OF RISK MINIMIZATION MEASURES ...................................................................... 61 
RISK MANAGEMENT PLAN - PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN ................... 63 
I. 
II. 
II.A 
II.B 
II.C 
II.C.1 
II.C.2 
THE MEDICINE AND WHAT IT IS USED FOR ............................................................................. 63 
RISKS ASSOCIATED WITH THE MEDICINE AND ACTIVITIES TO MINIMIZE OR 
FURTHER CHARACTERIZE THE RISKS ..................................................................................... 63 
List of important risks and missing information .............................................................................. 64 
Summary of important risks ........................................................................................................... 65 
Post-authorization development plan ............................................................................................. 67 
Studies which are conditions of the marketing authorization ......................................................... 67 
Other studies in post-authorization development plan ................................................................... 67 
REFERENCES .............................................................................................................................................. 69 
RISK MANAGEMENT PLAN - PART VII: ANNEXES .................................................................................. 72 
 
 
 
 
LIST OF TABLES  
Table 1 - RMP version to be assessed as part of this application .................................................................. 2 
Table 2 - Other RMP versions under evaluation ............................................................................................. 2 
Table 3 - Details of the currently approved RMP ............................................................................................ 2 
Table 4 - QPPV name and signature .............................................................................................................. 2 
Table 5 - Product Overview ............................................................................................................................. 9 
Table 6 - Epidemiology of the acid sphingomyelinase deficiency ................................................................. 12 
Table 7 - Key safety findings from non-clinical studies and relevance to human usage ............................... 17 
Table 8 - Acid Sphingomyelinase Deficiency Clinical Trials of Olipudase Alfa Treatment ............................ 20 
Table 9 - Acid Sphingomyelinase Deficiency Natural History Studies (no treatment with olipudase alfa 
administered) ................................................................................................................................................. 21 
Table 10 - Duration of exposure .................................................................................................................... 23 
Table 11 - Exposure by age group and gender ............................................................................................. 24 
Table 12 - Exposure by dose ......................................................................................................................... 27 
Table 13 - Exposure by ethnic origin ............................................................................................................. 29 
Table 14 - Exposure by race ......................................................................................................................... 30 
Table 15 - Exposure by baseline cirrhosis .................................................................................................... 32 
Table 16 - Important exclusion criteria in pivotal studies in the development program ................................ 34 
Table 17 - Exposure of special populations included or not in clinical trial development program ............... 35 
Table 18   Olipudase alfa worldwide sales - Sanofi (01 May 2020 to 30 September 2022a) in units ........... 38 
Table 19 - Important identified risk considered for inclusion in the list of safety concerns: Immunogenicity: 
Infusion associated reactions (IARs), systemic hypersensitivity including anaphylactic reactions, ADA 
mediated hypersensitivity reactions............................................................................................................... 43 
Table 20 - Important potential risk considered for inclusion in the list of safety concerns: Medication errors in 
home infusion setting ..................................................................................................................................... 44 
Table 21 - Important potential risk considered for inclusion in the list of safety concerns: Foetal toxicity .... 44 
Table 22 - Missing information considered for inclusion in the list of safety concerns: Use in lactating women
 ....................................................................................................................................................................... 44 
Table 23 - Missing information considered for inclusion in the list of safety concerns: Long-term safety 
(beyond 2 years) ............................................................................................................................................ 45 
Table 24   Important identified risk: Immunogenicity: Infusion associated reactions (IARs), systemic 
hypersensitivity including anaphylactic reactions, ADA mediated hypersensitivity reactions ....................... 46 
Table 25 - Important potential risk: Medication errors in home infusion setting ............................................ 48 
Table 26 - Important potential risk: Foetal toxicity ......................................................................................... 48 
Table 27 - Missing information: Use in lactating women ............................................................................... 49 
Table 28 - Missing information: Long-term safety (beyond 2 years) ............................................................. 49 
 
 
Table 29 - Additional pharmacovigilance activities (category 1 to 3) summary ............................................ 53 
Table 30 - Ongoing and planned additional pharmacovigilance activities .................................................... 54 
Table 31 - Description of routine risk minimization measures by safety concern ......................................... 58 
Table 32 - Additional risk minimization measures ......................................................................................... 59 
Table 33 - Summary table of pharmacovigilance activities and risk minimization activities by safety concern
 ....................................................................................................................................................................... 61 
Table 34 - List of important risks and missing information ............................................................................ 64 
Table 35 - Important identified risk with corresponding risk minimization activities and additional 
pharmacovigilance activities: Immunogenicity: Infusion associated reactions (IAR), systemic hypersensitivity 
including anaphylactic reactions, Anti-Drug Antibody (ADA) mediated hypersensitivity reactions ............... 65 
Table 36 - Important potential risk with corresponding risk minimization activities and additional 
pharmacovigilance activities: Medication errors in home infusion setting ..................................................... 65 
Table 37 - Important potential risk with corresponding risk minimization activities: Foetal toxicity ............... 66 
Table 38 - Missing information with corresponding risk minimization activities: Use in lactating women ..... 66 
Table 39 - Missing information with corresponding risk minimization activities and additional 
pharmacovigilance activities: Long-term safety (beyond 2 years) ................................................................ 67 
Table 40 - Other studies in post-authorization development plan ................................................................. 67 
 
 
 
 
ABBREVIATIONS  
Anti-Drug Antibody 
Adverse Event 
Adverse Event of Special Interest 
Acute Phase Reaction 
Acid Sphingomyelinase 
Acid Sphingomyelinase Deficiency 
Acid Sphingomyelinase Knock-Out 
Anatomical Therapeutic Chemical 
Biodistribution 
Body Mass Index 
Cluster of Differentiation 
Chinese Hamster Ovary 
Company Medical Query 
Central Nervous System 
Drug Abuse Liability Assessment 
Defined Daily Dose 
Drug-Drug Interaction 
Data Lock Point 
Data Monitoring Committee 
Deoxyribonucleic Acid 
Diphenhydramine 
Exposure-Adjusted Incident Rate 
Electrocardiogram 
Echocardiography 
Electronic Common Technical Document 
European Economic Area 
Emergency Investigational New Drug 
European Medicines Agency 
European Public Assessment Report 
Enzyme Replacement Therapy 
Extension Treatment Period 
European Union 
Functional Inhibitors of Acid Sphingomyelinase 
Granulocyte-Colony Stimulating Factor 
Good Laboratory Practice 
Healthcare Professional 
Human Immunodeficiency Virus 
Infusion Associated Reaction 
International Conference for Harmonization 
Immunoglobulin E 
Immunoglobulin G 
ADA: 
AE: 
AESI: 
APR: 
ASM: 
ASMD: 
ASMKO: 
ATC: 
BD: 
BMI: 
CD: 
CHO: 
CMQ: 
CNS: 
DALA: 
DDD: 
DDI: 
DLP: 
DMC: 
DNA: 
DPH: 
EAIR: 
ECG: 
ECHO: 
e-CTD: 
EEA: 
eIND: 
EMA: 
EPAR: 
ERT: 
ETP: 
EU: 
FIASMA: 
G-CSF: 
GLP: 
HCP: 
HIV: 
IAR: 
ICH: 
IgE: 
IgG: 
 
 
 
IL: 
IND: 
INN: 
INR: 
IP: 
IV: 
MAA: 
MAH: 
MARCO: 
Max: 
Min: 
MIP: 
MRI: 
N: 
NAb: 
NOAEL: 
NPD A: 
NPD B: 
NZW: 
PAP: 
PBRER: 
PD: 
PK: 
PL: 
PSUR: 
PT: 
PY: 
QPPV: 
QR: 
rhASM: 
RMP: 
SAE: 
SD: 
SM: 
SmPC: 
SMPD1: 
SRS: 
SSRI: 
TEAE: 
URL: 
US: 
WHO: 
WOCBP: 
Interleukin 
Investigational New Drug 
International Nonproprietary Name 
International Normalized Ratio 
Intraperitoneal 
Intravenous 
Marketing Authorization Application 
Marketing Authorization Holder 
Margin Consolidated 
Maximum 
Minimum 
Macrophage Inflammatory Protein 
Magnetic Resonance Imaging 
Number 
Neutralizing Antibody 
No-Observed-Adverse-Effect-Level 
Niemann-Pick Disease Type A 
Niemann-Pick Disease Type B 
New Zealand White 
Primary Analysis Period 
Periodic Benefit-Risk Evaluation Report 
Pharmacodynamic 
Pharmacokinetic 
Package Leaflet 
Periodic Safety Update Report 
Preferred Term 
Patient Year 
Qualified Person Responsible for Pharmacovigilance 
Quick Response 
Recombinant form of Human Acid Sphingomyelinase 
Risk Management Plan 
Serious Adverse Event 
Standard Deviation 
Sphingomyelin 
Summary of Product Characteristics 
Sphingomyelin Phosphodiesterase-1 Gene 
Splenomegaly Related Score 
Selective Serotonin Reuptake Inhibitor 
Treatment Emergent Adverse Event 
Uniform Resource Locator 
United States 
World Health Organization 
Women of Child Bearing Potential 
 
 
 
RISK MANAGEMENT PLAN - PART I: PRODUCT (S) OVERVIEW  
Table 5 - Product Overview  
Active substance(s) 
(INN or common name) 
Olipudase alfa 
Pharmacotherapeutic group(s) 
(ATC Code) 
A16AB25  
Marketing Authorization Holder 
Genzyme Europe B.V. 
Medicinal products to which this 
RMP refers 
1 
Invented name(s) in the EEA  
XENPOZYME 
Marketing authorization 
procedure 
Brief description of the product 
Centralized procedure 
Chemical class: 
Olipudase alfa is a rhASM developed as an ERT. 
Summary of mode action: 
Olipudase alfa catalyzes the hydrolysis of SM, reducing the amount of SM 
that accumulates in organs of patients with ASMD. 
Important information about its composition: 
Olipudase alfa is produced in a CHO cell line by recombinant DNA 
technology. 
Olipudase alfa is a sterile, lyophilized powder for concentrate for solution 
for infusion. 
Excipients: sucrose, L-methionine, sodium phosphate dibasic 
heptahydrate, sodium phosphate monobasic monohydrate. 
Refer to e-CTD sequence 0016 Module 1.3.1 English proposed Product 
Information. 
Current: 
Olipudase alfa is an enzyme replacement therapy for the treatment of 
non-CNS manifestations of ASMD in pediatric and adult patients with 
type A/B or type B. 
Proposed: 
Not applicable 
Current: 
Posology 
Initial treatment/dose escalation phase 
The rapid metabolism of accumulated SM by olipudase alfa generates 
proinflammatory breakdown products, which may induce IARs and/or 
transient liver enzyme elevations. A dose escalation regimen can minimize 
the majority of these AEs.  
Hyperlink to the product 
information 
Indication(s) in the EEA 
Dosage in the EEA 
 
Olipudase alfa dose is based on the actual body weight for patient with a 
BMI ≤30 or an optimal body weight for patient with a BMI >30. 
The recommended starting dose of olipudase alfa is 0.1 mg/kg for adults 
and the dose should be subsequently increased according to the dose 
escalation regimen presented in the table below: 
Adult patients (≥18 years old) 
First dose (Day 1) 
0.1 mg/kg 
Second dose (Week 2) 
0.3 mg/kg 
Third dose (Week 4) 
0.3 mg/kg 
Fourth dose (Week 6) 
0.6 mg/kg 
Fifth dose (Week 8) 
Sixth dose (Week 10) 
0.6 mg/kg 
1.0 mg/kg 
Seventh dose (Week 12) 
2.0 mg/kg 
Eighth dose (Week 14) 
3.0 mg/kg 
(recommended maintenance dose) 
Maintenance phase 
The recommended maintenance dose of olipudase alfa is 3 mg/kg 
every 2 weeks. 
Pediatric population 
The recommended starting dose of olipudase alfa is 0.03 mg/kg for 
pediatric patients and the dose should be subsequently increased 
according to the dose escalation regimen presented below: 
Pediatric patients (0 to <18 years old) 
First dose (Day 1) 
0.03 mg/kg 
Second dose (Week 2) 
0.1 mg/kg 
Third dose (Week 4) 
0.3 mg/kg 
Fourth dose (Week 6) 
0.3 mg/kg 
Fifth dose (Week 8) 
Sixth dose (Week 10) 
0.6 mg/kg 
0.6 mg/kg 
Seventh dose (Week 12) 
1.0 mg/kg 
Eighth dose (Week 14) 
2.0 mg/kg 
Ninth dose (Week 16) 
3.0 mg/kg 
(recommended maintenance dose) 
The recommended maintenance dose of olipudase alfa is 3 mg/kg 
every 2 weeks. 
Proposed: 
Not applicable 
 
Pharmaceutical form(s) and 
strength(s)  
Current: 
Powder for concentrate for solution for infusion. 
Each vial contains 20 mg of olipudase alfa. 
Proposed: 
Not applicable 
Is/will the product (be) subject to 
additional monitoring in the EU? 
Yes 
AE: Adverse Event; ASMD: Acid Sphingomyelinase Deficiency; ATC: Anatomical Therapeutic Chemical; BMI: Body Mass Index; 
CHO: Chinese Hamster Ovary; CNS: Central Nervous System; DNA: Deoxyribonucleic Acid; e-CTD: Electronic Common Technical 
Document; EEA: European Economic Area; ERT: Enzyme Replacement Therapy; EU: European Union; IAR: Infusion Associated 
Reaction; INN: International Nonproprietary Name; rhASM: Recombinant form of Human Acid Sphingomyelinase; RMP: Risk 
Management Plan; SM: Sphingomyelin. 
 
 
RISK MANAGEMENT PLAN - PART II MODULE SI: EPIDEMIOLOGY OF 
THE INDICATION(S) AND TARGET POPULATION(S)  
Olipudase alfa is an enzyme replacement therapy for the treatment of non-CNS manifestations of 
ASMD in pediatric and adult patients with type A/B or type B. The epidemiology of the disease is 
summarized in the following table. 
Table 6 - Epidemiology of the acid sphingomyelinase deficiency  
Indication 
Acid sphingomyelinase deficiency 
Incidence (birth 
prevalence) 
Acid sphingomyelinase deficiency is an autosomal recessive disease. The phenotype 
spectrum ranges from the severe infantile neurovisceral form (ASMD type A, historically 
known as NPD A) to the chronic visceral form (ASMD type B, NPD B), with an intermediate or 
chronic neurovisceral phenotypic presentation also being described (ASMD type A/B, 
NPD A/B). 
While ASMD type A is usually diagnosed before one year of age, the chronic forms are 
diagnosed during childhood or later, often after a patient presents with organomegaly. 
Misdiagnosis and delayed diagnosis are prevalent in this population due to the rarity of ASMD 
and the unfamiliarity of the specific signs and symptoms of the disease. (1) 
The rarity of the disease renders accurate estimations of incidence and prevalence difficult, 
and robust epidemiological data for ASMD in various regions are lacking. In particular, natural 
history studies are most often limited to small numbers of patients, and would not allow to 
derive incidence or prevalence data (no denominator). (2)(3) Disease frequency estimates 
have been based on clinically suspected cases referred for biochemical and genetic testing. 
Population-wide screening has not been performed, but genetic screening may be performed 
in patients from certain populations with common SMPD1 pathogenic variants, such as 
patients with Ashkenazi Jewish backgrounds. 
In a systematic review of birth prevalence studies, based on data from ASMD type A and B 
patients referred to biochemical testing facilities, the birth prevalence per 100 000 life-births 
was reported as 0.4 in Australia, 0.53 in the Netherlands, 0.6 in Northern Portugal, 0.33 in 
Czech Republic, and 0.25 in United Arab Emirates; (4) placing the birth incidence of ASMD at 
about 0.4 to 0.6 per 100 000 births. 
Newborn screening studies have reported an incidence of about 4 to 5 per 100 000. (5)(6) 
Acid sphingomyelinase deficiency is a pan-ethnic disease; however, there is a higher birth 
prevalence of ASMD type A disease among persons with Ashkenazi Jewish ancestry. 
(6)(7)(8) 
In the Ashkenazi Jewish population, the only population that performs DNA-based screening, 
the carrier frequency of the 3 common pathogenic variants (L302P, R496L, fsP330) known to 
cause ASMD type A is 1 in 90 individuals, corresponding to a birth prevalence of about 
3 per 100 000. (5)(9) In non-Jewish populations, the prevalence of ASMD type A is unknown, 
the sensitivity of carrier screening has not been established, and the pathogenic variants that 
account for the disease-causing changes may differ from those in Ashkenazi Jewish 
populations. (10) 
For chronic forms of ASMD, several factors contribute to the absence of accurate estimates of 
the prevalence, including under-diagnosis related to poor access to enzyme testing, 
misdiagnosis due to the high degree of variability in presenting symptoms, and/or lack of 
knowledge about chronic forms of ASMD in the clinical community. (4)(5)(7) The Orphanet 
survey estimated the prevalence of chronic forms of ASMD type B 
as 0.4 per 100 000 individuals (and a birth prevalence of 0.25 per 100 000 for type A). (8) The 
highest frequencies of chronic forms of ASMD have been reported in individuals of Turkish, 
 
Indication 
Acid sphingomyelinase deficiency 
Demographics of the 
population in the 
authorized indication 
Main existing treatment 
options 
Natural history of the 
indicated condition in 
the untreated 
population including 
mortality and morbidity 
Arabic, and North African descent, although the disorder affects many other distinct 
populations. (7) For example, estimates for the Chilean population based on the allele 
frequency of the p.(Ala359Asp) variant suggest a birth prevalence rate of about 2 cases 
per 100 000 births. (10) 
Acid Sphingomyelinase Deficiency is a multisystemic disorder with heterogeneous 
manifestations and represents a spectrum of disease, classified as:a (6) 
•  Acid Sphingomyelinase Deficiency type A or Infantile neurovisceral ASMD, historically 
known as NPD A, has onset during infancy with severe multiorgan manifestations and 
neurodegeneration, rapid progression and death typically by 3 years of age.  
•  Acid Sphingomyelinase Deficiency type B or Chronic visceral ASMD, historically known as 
NPD B, has a later onset and a variable progression rate and prognosis; patients may live 
into later adulthood but may be burdened with multiple morbidities, such as 
hepatosplenomegaly, progressive pulmonary dysfunction, thrombocytopenia, and 
dyslipidemia reflected in the clinically significant pulmonary, liver, and cardiac diseases 
that are common contributors to premature death in these patients. 
•  Acid Sphingomyelinase Deficiency type A/B or Chronic neurovisceral ASMD, historically 
known as variant NPD B, intermediate type or NPD type A/B, in which patients survive 
early childhood but exhibit multiorgan manifestations and progressive neurological 
abnormalities. The intermediate phenotypic presentations support a position that ASMD 
represents rather a continuum of clinical subtypes, with the ASMD type A and ASMD 
type B being two ends of the spectrum. 
No publications have distinguished an occurrence ratio among the forms of ASMD or 
estimated the relative proportion of adult and pediatric patients with ASMD. Clinical 
experience has been that ASMD is often diagnosed during childhood. Of the patients who 
present symptomatically with ASMD, approximately 60% are diagnosed while in the pediatric 
age group. (11) 
There is limited information in the literature regarding pregnancy in ASMD. Personal 
observations from one physician note that women with chronic visceral ASMD type B having 
a wide range of disease manifestations including significant pulmonary disease and 
hepatosplenomegaly, appear to have normal pregnancies and healthy newborns. During 
pregnancy and the perinatal period, esophageal varices contribute to increased bleeding 
risks. (12) 
To date, only symptomatic therapy is available. This includes lifestyle and diet modifications, 
statin therapy to lower cholesterol levels, supplemental oxygen, bronchodilators, vaccinations 
as appropriate for patients with underlying lung disease, vaccinations against viral hepatitis A 
and B, and blood transfusions to treat patients with acute episodes of bleeding due to 
splenomegaly and low platelet counts. 
Several attempts have been made to use cellular and solid organ transplantation as an 
indirect source of ASM replacement therapy. The experience to date with cell and organ 
transplantation has been limited. (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24) 
Early diagnosis and appropriate management are essential for reducing the risk of 
complications, improving quality of life, and addressing disease complications. 
Almost all patients with ASMD have massive hepatosplenomegaly and an atherogenic lipid 
profile (cholesterol abnormalities), (6)(12)(25)(26) and most patients have interstitial lung 
disease with progressive impairment of pulmonary function and hematologic abnormalities 
including markedly reduced platelet counts from an early age. (27)(28) Other common clinical 
manifestations include liver dysfunction, and growth delays. (6)(11)(26) 
Patients with ASMD type A have severe neurologic manifestations. ASMD type A has a rapid 
and fatal neurodegenerative course and uniformly leads to death by 3 years of age. 
 
Indication 
Acid sphingomyelinase deficiency 
Patients with ASMD type B often survive into adulthood or can be diagnosed in the adulthood 
and have multi-systemic manifestations, including significant splenomegaly and 
hepatomegaly, progressive pulmonary dysfunction, musculoskeletal problems, 
thrombocytopenia, and dyslipidemia. (6) Greater than 80% of patients with ASMD type B 
have radiographic evidence of infiltrative lung disease, although some patients may not have 
overt symptoms. (27)(28) The most common symptoms include dyspnea, shortness of breath 
and bruising, fatigue, abdominal pain/discomfort, diarrhea, frequent bleedings, pulmonary 
infections, joint/limb pain, muscle weakness/cramps, as well as numbness and tingling in 
extremities. The disease interferes with functioning and activities of daily living, often leading 
to chronic fatigue, limited physical or social activity and difficulties in performing daily activities 
or work. 
Patients with ASMD type A/B have the disease manifestations mentioned above for ASMD 
type B, but also present with progressive neurologic manifestations resulting in a significantly 
shorter life span than those with ASMD type B. (6) 
Chronic forms of ASMD have a progressive course. (2) Clinically significant pulmonary, 
hepatic, bleeding and cardiac complications are common causes of mortality. (29) In patients 
with chronic forms of ASMD (type A/B and B), the prognosis is more variable than with ASMD 
type A. (6) In general, chronic forms of ASMD have a later onset and a variable prognosis; 
nevertheless pediatric patients with more severe manifestations of chronic ASMD are at 
particular risk for early mortality. (6) Patients with ASMD type A/B have a chronic, progressive 
disease that is considerably less severe than ASMD type A, but still carries a worse prognosis 
than ASMD type B. (30) Some patients with ASMD type B live into their 20s and possibly up 
to their 70s. A case series of 78 deceased patients with chronic forms of ASMD found a 
median age at death of 23.5 (range 0.58 to 72) years for ASMD type B 
and 8.5 (range 2 to 32) years for ASMD type A/B. (25) Many patients die before or in early 
adulthood, often from pneumonia/respiratory failure or liver failure. Mortality data for chronic 
forms of ASMD are limited. (2)(11) In an 11-year natural history study, which included patients 
with ASMD type B and A/B, 8 patients died of causes related to ASMD. Six deaths occurred 
before age 50 with three occurring before age 20. Individuals with either severe splenomegaly 
or prior splenectomy were ten times more likely to have died during the follow-up period than 
those with smaller or intact spleens. 
Other than the genetic background, no other specificity or risk factor related to the target 
population has been identified. Therefore, it may be expected that any co-morbidities that are 
not related to the disease itself in the treated population, and not impacted by the disease 
itself, may be broadly similar to those in the general population. However, given the severity 
and variability of the disease spectrum, and the rarity of the disease itself, it is challenging to 
postulate or to establish whether or not a given comorbidity should be considered as 
independent from such a spectrum (ie, not influenced by ASMD disease itself). For example, 
antidepressant use has been reported in several patients with ASMD type B disease, but 
such data are limited due to the rarity of the disease; (31) hence it is challenging to establish 
whether or not ASMD patients have a higher risk of depression and to quantify such a risk. 
Important 
co-morbidities 
a  This document uses “chronic forms of ASMD” to refer to a combined category of patients with chronic visceral and chronic 
neurovisceral disease. 
ASM: Acid Sphingomyelinase; ASMD: Acid Sphingomyelinase Deficiency; DNA: Deoxyribonucleic Acid; NPD A: Niemann-Pick Disease 
Type A; NPD B: Niemann-Pick Disease Type B; SMPD1: Sphingomyelin Phosphodiesterase-1 Gene. 
 
RISK MANAGEMENT PLAN - PART II MODULE SII: NON-CLINICAL PART 
OF THE SAFETY SPECIFICATION  
Preclinical development of olipudase alfa 
A comprehensive non-clinical research program was conducted with olipudase alfa in a number of 
species and at a range of doses and dosing regimens. Animals in all studies were dosed 
intravenously, either as a bolus injection or infusion, as this is the route of administration used in 
patients (one exception was a study evaluating the subcutaneous route). These studies demonstrate 
that olipudase alfa safely and effectively metabolizes SM (32) in a mouse model of ASMD when a 
dose escalation regimen is used. The acid sphingomyelinase knock-out (ASMKO) mouse is a model 
of ASMD Type A (33) that lacks ASM activity. These ASMKO mice were used to evaluate the 
pharmacokinetic (PK), biodistribution (BD), and pharmacodynamic (PD) of olipudase alfa 
following administration of clinically relevant doses. Since the ASMKO mice accumulate SM in 
target organs such as the liver, spleen and lungs, they can be used to evaluate the PD effects of 
olipudase alfa administration on SM reduction. These animals show a significant neurological 
phenotype that resembles neuropathic ASMD but this phenotype was not assessed in the 
non-clinical studies because olipudase alfa does not cross the blood brain barrier. 
Toxicity studies were conducted in BALB/C mice, C57BL/6 mice, cluster of differentiation (CD-1) 
mice, ASMKO mice, Sprague-Dawley rats, beagle dogs, New Zealand White (NZW) rabbits, and 
cynomolgus monkeys. Study regimens varied from a single administration, dose escalation, to 
every other week administration for up to 6 months to support lifetime administration in ASMD 
patients. In studies conducted in BALB/c mice, C57Bl/6 mice, CD-1 mice, NZW rabbits, 
Sprague-Dawley rats, beagle dogs, and cynomolgous monkeys, olipudase alfa was well-tolerated. 
Doses selected in the pivotal toxicity studies (3 to 30 mg/kg) were based on available data. The high 
dose was the maximum feasible dose based on olipudase alfa concentrations for the first batches, 
and for later batches represented a 10-fold dose margin over the high dose to be used clinically. The 
highest clinical dose was selected as the low dose in the pivotal toxicity studies. 
The ASMKO mouse was considered to be the most sensitive toxicological species with acute 
toxicity findings at doses ≥10 mg/kg following a single dose in this species, whereas no toxicity 
was observed in all other species evaluated at doses up to 30 mg/kg. The lack of adverse findings at 
comparable olipudase alfa doses and exposures in the other non-clinical species evaluated 
suggested that the dose-related toxicity observed in ASMKO mice may be due to the rate and 
amount of substrate degradation. 
Adverse effects, including mortality, were observed in ASMKO mice administered olipudase alfa 
doses ≥10 mg/kg. Studies to evaluate these adverse effects were performed in ASMKO and 
C57BL/6 mice. There was a dose responsive increase in cytokines (interleukin [IL]-6, 
Granulocyte-Colony Stimulating Factor [G-CSF], IL-1α, IL-1β, and macrophage inflammatory 
protein [MIP]-1α) following a single administration of olipudase alfa at 3, 10, or 20 mg/kg, with no 
notable increases in cytokines observed at 0.3 mg/kg in the ASMKO mouse or at a single dose 
of 20 mg/kg of olipudase alfa in C57BL/6 mice. Concentrations of ceramide, sphingosine, and 
sphingosine-1-phosphate (catabolites of the accumulated SM) were increased following high doses 
of olipudase alfa (≥10 mg/kg) in the ASMKO mouse, similar to that seen for cytokines. 
 
These results suggested that a dose escalation regimen may be necessary to reduce the toxic 
response at higher olipudase alfa doses. 
To test the hypothesis that the rapid accumulation of SM catabolites are responsible for the toxicity 
observed in the ASMKO mice, and upon request of Health Authorities to explore the mechanism of 
toxicity, repeat-dose studies were conducted to determine if a more gradual reduction in SM 
through dose escalation regimens could reduce the toxicity observed with a single high dose of 
olipudase alfa. When ASMKO mice received 4 IV doses of 3 mg/kg administered every other day, 
followed by a single IV dose of 20 mg/kg, 72 hours later, no mortality was observed and other 
toxicity findings were reduced in severity. Additionally, increases in cytokine and ceramide 
concentrations in the serum were reduced with this dose escalation regimen. Results from this study 
suggested that increased plasma concentrations of both total and C16-ceramide correlated with 
increased lethality and poor clinical outcome. When olipudase alfa (3 mg/kg) was administered 
once a week to ASMKO mice in a dose escalation regimen, instead of every other day, prior to a 
bolus dose of 20 mg/kg, olipudase alfa was also well-tolerated. Furthermore, in a study where 
ASMKO mice were administered olipudase alfa at 3 mg/kg every other day for 4 doses followed by 
doses of 3, 10, or 30 mg/kg every other week for 13 weeks (7 total doses), olipudase alfa was 
well-tolerated with an no-observed-adverse-effect-level (NOAEL) of 30 mg/kg. 
One study was performed to evaluate the potential PD drug interaction of two functional inhibitors 
of acid sphingomyelinase (FIASMAs). Functional inhibitors of ASM are a large group of cationic 
amphiphilic molecules that may disrupt the interaction of ASM with the lysosomal membrane. (34) 
Most FIASMAs have been identified by in silico analysis and substantial in vitro or in vivo data is 
lacking. Two common antidepressant drugs (citalopram and fluoxetine) with variable levels of 
predicted inhibitory activity against ASM were co-administered with olipudase alfa to evaluate their 
impact on PD response. Fluoxetine and citalopram were selected because they belong to the same 
class of drugs, selective serotonin reuptake inhibitors (SSRIs), and demonstrated different levels of 
inhibitory activity in vitro. Fluoxetine is predicted to be the more potent inhibitor with 
approximately 13% residual ASM activity remaining in an in vitro inhibitor assay whereas 
incubation with citalopram resulted in approximately 80% residual ASM activity. (35) The effect of 
fluoxetine and citalopram on SM reduction following a single administration of 1 mg/kg olipudase 
alfa was then evaluated in the spleen and liver of ASMKO mice. Fluoxetine did not impact 
olipudase alfa-mediated SM reduction in the liver and spleen despite previous in vitro data 
demonstrating robust ASM inhibition. Co-administration of citalopram did not impact olipudase 
alfa-mediated SM clearance in the liver. However, spleen SM levels were not significantly reduced 
compared to vehicle controls following co-administration of citalopram and olipudase alfa. These 
levels were not significantly different from the SM content in spleen from animals administered 
olipudase alfa alone, suggesting that this result may reflect the variability in PD effect at this dose 
rather than a true effect of citalopram inhibition. The inhibitor levels were in the lower end of the 
therapeutic range for both citalopram and fluoxetine, limiting the interpretation of these results. The 
data from this study suggest that fluoxetine is not a FIASMA in vivo, but a conclusion cannot be 
made regarding the inhibitory activity of citalopram. 
Developmental and reproductive toxicity studies were conducted in CD-1 mice and NZW rabbits at 
doses up to 30 mg/kg. No olipudase alfa-related adverse effects were observed at the highest dose 
of olipudase alfa evaluated, 30 mg/kg, in a male and female fertility study in CD-1 mice, in an 
embryo-foetal toxicity study in NZW rabbits, or in a pre-/postnatal developmental toxicity study in 
CD-1 mice. An increased incidence of exencephaly was observed when pregnant mice were treated 
 
daily with olipudase alfa at exposure levels less than the human exposure at the recommended 
maintenance therapeutic dose and frequency. This incidence was slightly higher than historical 
control data. The relevance of this observation for humans is unknown. The daily IV administration 
of olipudase alfa to pregnant rabbits did not result in foetal malformations or variations at exposures 
significantly exceeding the human exposure at the recommended maintenance therapeutic dose and 
frequency. The developmental NOAELs in mice and rabbits are 3 and 30 mg/kg/day. 
No juvenile toxicity studies were conducted. Juvenile toxicity studies in non-diseased animals 
would not provide information that is not already available in the described toxicity program. The 
ASMKO mouse is the most sensitive species, but unfortunately cannot be used for juvenile toxicity 
studies due to reproductive and neurological deficiencies in this mouse model. ASMKO mice have 
decreased litters, decreased numbers of pups, decreased sperm motility and sperm morphology 
issues, as well as decreased body size and increased cholesterol concentrations. ASMKO mice 
develop ataxia and neurological deficiencies by 2 to 4 months of age and die 
between 6 and 8 months of age. As olipudase alfa does not cross the blood-brain barrier, both 
treated and control groups would show similar background neurobehavioral abnormalities. These 
abnormalities, combined with resulting lethargy and ultimately death, renders distinguishing the 
ASMKO phenotype from potential toxicity difficult; neurobehavioral evaluations could not be 
adequately conducted. 
Single dose BD studies were also conducted in CD-1 mice to evaluate the distribution of olipudase 
alfa to the milk of lactating mice and to the fetus of pregnant mice. Olipudase alfa was not detected 
in fetuses from pregnant CD-1 mice administered a single dose of 3 mg/kg on E15. However, 
significant levels of olipudase alfa were measured in the milk of lactating mice 2 days following 
administration of 3 mg/kg. 
The key non-clinical findings are presented in the following table: 
Table 7 - Key safety findings from non-clinical studies and relevance to human usage  
Key Safety Findings  
Relevance to human usage 
Toxicity 
Toxicity 
•  Toxicity studies conducted in ASMKO mice, 
CD-1 mice, BALB/c mice, C57Bl/6 mice, 
Sprague-Dawley rats, NZW rabbits, beagle dogs, and 
cynomolgus monkeys, support the safety of olipudase 
alfa for clinical administration to ASMD patients at 
doses up to 3 mg/kg in conjunction with a dose 
escalation dose regimen. 
•  Adverse effects, including mortality, were observed in 
ASMKO mice administered olipudase alfa 
doses ≥10 mg/kg. Studies to evaluate these adverse 
effects were performed in ASMKO and C57BL/6 mice. 
Microscopic findings following a single dose included 
ballooning degeneration (≥1 mg/kg) and inflammatory 
foci noted in the liver (≥0.1 mg/kg) as well as adrenal 
gland congestion/hemorrhage (≥1 mg/kg). There was 
a dose-responsive increase in cytokines (IL6, G-CSF, 
IL-1α, IL-1β, and MIP-1α) following a single 
administration of olipudase alfa at 3, 10, or 20 mg/kg, 
with no notable increases in cytokines observed at 
•  Toxicity studies conducted in ASMKO mice, CD-1 mice, 
BALB/c mice, C57Bl/6 mice, Sprague-Dawley rats, NZW 
rabbits, beagle dogs, and cynomolgus monkeys, support 
the safety of olipudase alfa for clinical administration to 
ASMD patients at doses up to 3 mg/kg in conjunction with 
a dose escalation dose regimen. This dose escalation 
regimen has been implemented in all clinical studies 
starting with the Phase 1b trial (multiple ascending dose) 
and is part of the label. 
•  Transient elevations in transaminases during dose 
escalation have been observed in clinical trials, and do not 
raise a concern; no other findings indicating hepatoxicity 
were observed.  
•  Infusion associated reactions of systemic hypersensitivity 
(a majority of which were mild/moderate in intensity) 
including anaphylactic reactions, antibody mediated 
hypersensitivity reactions were seen in clinical trials. 
Immunogenicity is considered as an important identified 
risk (see [Part II SVII]).  
 
Key Safety Findings  
Relevance to human usage 
0.3 mg/kg in the ASMKO mouse or at a single dose of 
20 mg/kg of olipudase alfa in C57BL/6 mice. 
Concentrations of ceramide, sphingosine, and 
sphingosine-1-phosphate (catabolites of the 
accumulated SM) were increased following high doses 
of olipudase alfa (≥10 mg/kg) in the ASMKO mouse, 
similar to that seen for cytokines. However, the toxicity 
can be ameliorated if a dose escalation dosing 
regimen is employed. Intravenous olipudase alfa at 
doses of 3 mg/kg administered to ASMKO mice every 
other day for four doses followed by doses of 3, 10, or 
30 mg/kg every other week for 13 weeks (7 total 
doses) was well-tolerated. No increases in 
transaminases or adverse microscopic changes in the 
liver were observed. 
•  Hypersensitivity reactions to olipudase alfa, a human 
protein, were sometimes observed, most notably in 
mice and rats with repeated administrations, which 
necessitated pre-treatment/post-treatment with DPH; 
IP administration. 
•  An increased incidence of exencephaly was observed 
when pregnant mice were treated daily with olipudase 
alfa intravenously at exposure less than the human 
exposure at the recommended maintenance 
therapeutic dose and frequency. This incidence was 
slightly higher than historical control data. The daily IV 
administration of olipudase alfa to pregnant rabbits did 
not result in foetal malformations or variations at 
exposures significantly exceeding the human exposure 
at the recommended maintenance therapeutic dose 
and frequency. 
•  No serious and/or severe APRs have been observed in 
clinical trials. 
•  Studies with olipudase alfa have not been performed in 
pregnant women. As with any investigational drug product, 
there may be a risk of congenital anomalies. The relevance 
of this observation in mice for humans is unknown. Results 
from animal studies are not always predictive with respect 
to effects on pregnancy, embryonic/foetal development, 
parturition, and postnatal development. Therefore, the 
potential reproductive toxicity and risks for humans are 
unknown. 
•  As studies in animals have shown reproductive toxicity, 
“foetal toxicity” is considered an important potential risk in 
the RMP (see [Part II SVII]). 
•  Measurable levels of olipudase alfa were detected in 
•  The use of olipudase alfa in lactating women is considered 
the milk of lactating mice 2 days following 
administration of 3 mg/kg. 
missing information in the RMP (see [Part II SVII]). 
Safety pharmacology  
Safety pharmacology  
•  A GLP safety pharmacology study was conducted in 
cynomolgus monkeys and cardiovascular, respiratory, 
and CNS evaluations performed as part of the GLP 
single dose study of olipudase alfa in beagle dogs. 
Endpoints encompassed the core battery as defined in 
the ICH S7A and S7B guidelines. The results indicated 
that there were no test article-related changes in 
neurobehavioral or ECG parameters, heart rate, body 
temperature, activity or respiratory rate following 
administration at the highest dose of 30 mg/kg IV. 
•  A dose-dependent reduction in heart rate following a 
•  There were no severe cardiac events reported in the 
clinical studies. There was one SAE of extrasystoles 
moderate severity, which was considered by the 
investigator as treatment related, in a patient with a history 
of cardiomyopathy;  
•  The event occurred over 72-hours after infusion and 
resolved within 90 minutes; the patient has continued in 
the study. 
•  The potentially adverse effect of olipudase alfa on the 
cardiac function in humans has been mitigated by the dose 
escalation regimen. 
single olipudase alfa administration at 3, 10, 
and 20 mg/kg in ASMKO mice occurred at 
approximately 60 minutes post-dose, which was 
accompanied by a decrease in motor activity and 
followed by a slow decline in blood pressure beginning 
approximately 130 to 140 minutes post-dose. In 
addition, cardiac function (hemodynamic response, 
heart rate, blood pressure, and activity) was measured 
 
Key Safety Findings  
Relevance to human usage 
following two doses of olipudase alfa 
at 3 and 10 mg/kg and, while a slight decline in heart 
rate was noted following the second olipudase alfa 
administration, the heart rate did not drop 
below 550 beats per minute. These data suggest that 
a controlled release of SM catabolites following 
repeated low dose administration of olipudase alfa 
would not negatively impact cardiac function. 
•  No adverse effects on cardiac function have been 
observed in ASMKO mice when olipudase alfa was 
administered via a dose escalation regimen. 
Other toxicity-related information or data 
Not applicable 
Not applicable 
APR: Acute Phase Reaction; ASMD: Acid Sphingomyelinase Deficiency; ASMKO: Acid Sphingomyelinase Knock-Out; CD: Cluster of 
Differentiation; CNS: Central Nervous System; DPH: Diphenhydramine; ECG: Electrocardiogram; G-CSF: Granulocyte-Colony 
Stimulating Factor; GLP: Good Laboratory Practice; ICH: International Conference for Harmonization; IL: Interleukin; IP: Intraperitoneal; 
IV: Intravenous; MIP: Macrophage Inflammatory Protein; NZW: New Zealand White; RMP: Risk Management Plan; SAE: Serious 
Adverse Event; SM: Sphingomyelin. 
No additional non-clinical data have been collected on the use of olipudase alfa in any special 
populations. 
Olipudase alfa is an ERT not expected to be genotoxic or carcinogenic, and no studies have been 
conducted consistent with ICH Guideline S6 (R1) “Preclinical Safety Evaluation of 
Biotechnology-Derived Pharmaceuticals” to examine its genotoxic, mutagenic, or carcinogenic 
potential. 
In conclusion, toxicity studies conducted in ASMKO mice, CD-1 mice, BALB/c mice, 
C57Bl/6 mice, Sprague-Dawley rats, NZW rabbits, beagle dogs, and cynomolgus monkeys, support 
the safety of olipudase alfa for clinical administration to ASMD patients at doses up to 3 mg/kg in 
conjunction with a dose escalation dose regimen.
 
 
RISK MANAGEMENT PLAN - PART II MODULE SIII: CLINICAL TRIAL 
EXPOSURE  
The clinical development program for olipudase alfa in ASMD includes 5 clinical trials with 
olipudase alfa treatment and 5 non-interventional natural history studies without olipudase alfa 
treatment (See Table 8 and Table 9). 
Table 8 - Acid Sphingomyelinase Deficiency Clinical Trials of Olipudase Alfa Treatment  
Protocol 
Number 
Phase 
Age 
Category 
Protocol 
Title 
SPHINGO-
006-05 
1a 
Adult 
1b 
Adult 
DFI13412 
(SPHINGO-
008-12) 
1/2 
Pediatric  
DFI13803 
(ASCEND-
Peds) 
LTS13632a 
2 
Pediatric/ 
Adult 
A Phase 1, 
Single-center, 
Single-dose, 
Dose 
Escalation 
Study of rhASM 
in Adults with 
ASMD 
An Open-label, 
Multicenter, 
Ascending 
Dose Study of 
the Tolerability 
and Safety of 
rhASM in 
Patients with 
ASMD 
A Phase 1/2, 
Multicenter, 
Open-Label, 
Ascending 
Dose Study to 
Evaluate the 
Safety, 
Tolerability, 
PKs, PDs and 
Exploratory 
Efficacy of 
Olipudase alfa 
in Pediatric 
Patients 
Aged <18 years 
with ASMD 
A Long-Term 
Study to 
Assess the 
Ongoing Safety 
Duration 
of 
Treatment 
Study 
Status 
Single dose 
Complete 
26 weeks 
Complete 
64 weeks 
Complete 
Number 
of 
Patients 
11 
5 (4 from 
SPHINGO-
006-05) 
20 
Treatment 
Single arm, 
single dose of 
olipudase alfa 
(0.03, 0.1, 
0.3, 0.6, 
1.0 mg/kg), no 
dose escalation 
Single arm, 
within patient 
dose escalation 
of 0.03 mg/kg 
(pediatric) or 
0.1 mg/kg 
(adults) up to 
3.0 mg/kg, 
IV infusion of 
rhASM 
every 2 weeks 
Single arm, 
Within patient 
dose escalation 
of 0.03 mg/kg 
up to 3.0 mg/kg 
IV infusion of 
rhASM every 
2 weeks. 
25 (5 adult 
+ 20  
Single arm, 
Patients will 
receive an IV 
Up to 9 years 
or marketing 
approval 
Ongoing 
 
Protocol 
Number 
Phase 
Age 
Category 
Protocol 
Title 
DFI12712 
ASCEND 
2/3 
Adult 
and Efficacy of 
Olipudase alfa 
in Patients With 
ASMD 
A Phase 2/3, 
Multicenter, 
Randomized, 
Double-Blinded, 
Placebo-Contro
lled, 
Repeat-Dose 
Study to 
Evaluate the 
Efficacy, 
Safety, PDs, 
and PKs of 
Olipudase Alfa 
in Patients with 
ASMD 
Duration 
of 
Treatment 
Study 
Status 
52 weeks 
PAP and up 
to 4 years 
and 3 months 
extension 
PAP 
Complete 
ETP 
Ongoing 
Number 
of 
Patients 
pediatric 
patients) 
36 (1 from 
SPHINGO-
006-05) 
Treatment 
infusion of 
olipudase alfa 
every 2 weeks 
(± 3 days) at 
the same dose 
they were 
receiving at the 
end of the 
primary study.  
1:1 
Randomization 
to placebo or 
olipudase alfa, 
blinded, within 
patient dose 
escalation of 
0.1 mg/kg up to 
3.0 mg/kg, IV 
infusion of 
rhASM every 
2 weeks 
LTS13632 includes 5 adult patients from DFI13412 (SPHINGO-008-12) and 20 pediatric patients from DFI13803 (ASCEND-Peds)  
a 
ASMD: Acid Sphingomyelinase Deficiency; ETP: Extension Treatment Period; IV: Intravenous; PAP: Primary Analysis Period; 
PD: Pharmacodynamic; PK: Pharmacokinetic; rhASM; Recombinant form of Human Acid Sphingomyelinase. 
Table 9 - Acid Sphingomyelinase Deficiency Natural History Studies (no treatment with olipudase alfa 
administered)  
Protocol 
Number 
Age Category  Study Design 
SPHINGO-001-00  
Pediatric/Adult 
SPHINGO-003-02 
Adult 
RHASHC09538 
Pediatric 
RHASHC09539 
Pediatric 
A Multicenter, multi-national prospective, 
cross sectional survey study of patients 
with NPD B 
Multicenter, multi-national, Retrospective 
Natural History Study of Patients with ASM 
Deficiency 
Number of 
Patients 
59 (30 Pediatric 
and 29 Adult) 
Study 
Status 
Complete 
100 
Complete 
Natural History of ASMD During Childhood 
and Adolescence: A Retrospective 
Observational Study (US) 
1 
Complete 
Natural History of ASMD Among European 
Patients During Childhood and 
Adolescence: A Retrospective 
Observational Study 
approximately 20  Complete 
 
Protocol 
Number 
PIR16183 
Age Category  Study Design 
Number of 
Patients 
Pediatric/Adult 
A prospective and retrospective cohort 
study to refine and expand the knowledge 
on patients with chronic forms of ASMD 
87 
Study 
Status 
Ongoing 
ASM: Acid Sphingomyelinase; ASMD: Acid Sphingomyelinase Deficiency; NPD B: Niemann-Pick Disease Type B; US: United States. 
Overall Clinical trial exposure for the 5 olipudase alfa studies  
Eleven patients were treated in the single-dose Phase 1a trial (SPHINGO00605). The phase 1b trial 
DFI13412 enrolled 5 patients and 1 patient who had not been exposed to olipudase alfa (4 of whom 
had already participated in the phase 1a trial). Therefore, there were 12 adult patients who were 
exposed to olipudase alfa in completed trials. All 5 patients who completed DFI13412 were rolled 
over to the ongoing long-term study LTS13632. 
Ongoing study DFI12712 ASCEND enrolled 36 patients, including one who was previously 
exposed to olipudase alfa in SPHINGO00605. One patient who had not previously received 
olipudase alfa was randomized to placebo and discontinued from the study without ever receiving 
olipudase alfa. Therefore, 34 patients were newly exposed to olipudase alfa in the ongoing 
DFI12712 study. 
Overall, 46 adult patients have been exposed to olipudase alfa in both completed and ongoing 
studies. 
There were 20 pediatric patients enrolled in the DFI13803 study, 4 adolescents (12 to <18 years of 
age), 9 children (6 to <12 years of age), and 7 infants/early children (birth to <6 years of age). All 
patients completed the trial and are now enrolled in the ongoing long-term study LTS13632. 
Therefore, a total of 66 patients (46 adult and 20 pediatric) have been exposed to olipudase alfa. 
Six (6) adults from phase 1a study (single dose study) did not enroll into phase 1b or DFI12712 
study. Thus, following tables summarize the exposure for all olipudase alfa exposed patients in 
multiple dose studies (DFI13412, DFI12712, DFI13803 and LTS13632) including 40 adults (5 from 
phase 1b and 35 from DFI12721) and 20 pediatric patients. 
 
Table 10 shows duration of exposure. Overall, sixty patients had a median of 3.11 years (range 0.4 to 7.8) of exposure to olipudase alfa. Almost all 
patients (98.3%) received ≥1 year of olipudase alfa treatment, 88.3% received ≥2 years of treatment, and 51.7% received ≥3 years of treatment. 
The treatment exposure was larger in adult patients than pediatric patients. 
Table 10 - Duration of exposure  
Extent of Treatment Exposure 
Cumulative duration of olipudase alfa exposure (patient-years) 
Duration on olipudase alfa (years) 
  Number of patients with value 
  Mean (SD) 
  Median 
  Min : Max 
Distribution of duration on olipudase alfa, n (%) 
>0 to <1 year 
  ≥1 to <2 years 
  ≥2 to <3 years 
  ≥3 to <4 years 
  ≥4 to <5 years 
  ≥5 to <6 years 
  ≥6 to <7 years 
  ≥7 years 
Pediatric 
(N = 20) 
80.29 
20 
4.01 (1.195) 
4.15 
2.5 : 5.7 
0 
0 
7 (35.0%) 
2 (10.0%) 
7 (35.0%) 
4 (20.0%) 
0 
0 
Adult 
(N = 40) 
135.78 
40 
3.39 (1.868) 
2.95 
0.4 : 7.8 
1 (2.5%) 
6 (15.0%) 
15 (37.5%) 
9 (22.5%) 
4 (10.0%) 
0 
0 
5 (12.5%) 
Overall 
(N = 60) 
216.08 
60 
3.60 (1.689) 
3.11 
0.4 : 7.8 
1 (1.7%) 
6 (10.0%) 
22 (36.7%) 
11 (18.3%) 
11 (18.3%) 
4 (6.7%) 
0 
5 (8.3%) 
Cumulative distribution of duration on olipudase alfa, n (%) (patient-years) 
>0 year 
  ≥1 year 
  ≥2 years 
20 (100.0%) (80.29) 
20 (100.0%) (80.29) 
20 (100.0%) (80.29) 
40 (100.0%) (135.78) 
60 (100.0%) (216.08) 
39 (97.5%) (135.40) 
33 (82.5%) (124.98) 
59 (98.3%) (215.69) 
53 (88.3%) (205.27) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extent of Treatment Exposure 
  ≥3 years 
  ≥4 years 
  ≥5 years 
  ≥6 years 
  ≥7 years 
Pediatric 
(N = 20) 
13 (65.0%) (61.70) 
11 (55.0%) (54.63) 
4 (20.0%) (22.49) 
0 (0) 
0 (0) 
Adult 
(N = 40) 
18 (45.0%) (86.84) 
9 (22.5%) (56.04) 
5 (12.5%) (38.63) 
5 (12.5%) (38.63) 
5 (12.5%) (38.63) 
Overall 
(N = 60) 
31 (51.7%) (148.54) 
20 (33.3%) (110.66) 
9 (15.0%) (61.12) 
5 (8.3%) (38.63) 
5 (8.3%) (38.63) 
Duration on olipudase alfa in initial dose escalation period (years) 
  Number of patients with value 
  Mean (SD) 
20 
0.38 (0.147) 
40 
0.32 (0.166) 
60 
0.34 (0.161) 
  Median 
  Min : Max 
Percentages are based on the number of safety set in each group. 
Initial dose escalation period is the first time when patient reached the 3 mg/kg; or if a patient never reached 3 mg/kg, then the cut would be the first time the patient maintains the maximum tolerated 
dose consecutively for 6 visits. 
PGM=PRODOPS/GZ402665/OVERALL/ISS_2021/REPORT/PGM/cdc_exposure_t.sas OUT=REPORT/OUTPUT/cdc_exposure_t_i.rtf (22JUN2021 - 6:47)  
Max: Maximum; Min: Minimum; N: Number; SD: Standard Deviation. 
0.27 
0.2 : 1.2 
0.29 
0.2 : 1.2 
0.34 
0.3 : 1.0 
Table 11 shows exposure by age group and gender. Overall, sixty patients received 216.08 patient-years of olipudase alfa. The treatment exposure 
among the 40 adult patients, 135.78 patient-years was higher than in the 20 pediatric patients, 80.29 patient-years. 
Table 11 - Exposure by age group and gender  
Infant/early child 
(<6 years old)  
Female 
(N = 4) 
Male 
(N = 3) 
Child (6 to <12 years 
old) 
Female 
(N = 5) 
Male 
(N = 4) 
Adolescent (12 to 
<18 years old) 
Female 
(N = 1) 
Male 
(N = 3) 
Adult (18 to 
<65 years old) 
Female 
(N = 23) 
Male 
(N = 16) 
Elderly Adult 
(≥65 years old) 
Male 
Female 
(N = 0) 
(N = 1) 
13.43 
9.50 
19.82 
15.06 
5.73 
16.76 
71.78 
62.52 
1.48 
0 
Extent of Treatment 
Exposure 
Cumulative duration of 
olipudase alfa exposure 
(patient-years) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Infant/early child 
(<6 years old)  
Female 
(N = 4) 
Male 
(N = 3) 
Child (6 to <12 years 
old) 
Female 
(N = 5) 
Male 
(N = 4) 
Adolescent (12 to 
<18 years old) 
Female 
(N = 1) 
Male 
(N = 3) 
Adult (18 to 
<65 years old) 
Female 
(N = 23) 
Male 
(N = 16) 
Elderly Adult 
(≥65 years old) 
Male 
Female 
(N = 0) 
(N = 1) 
Extent of Treatment 
Exposure 
Duration on olipudase alfa 
(years) 
  Number of patients with value 
4 
  Mean (SD) 
3.36 (0.802) 
  Median 
  Min : Max 
3.35 
2.6 : 4.2 
3 
3.17 
(0.858) 
2.85 
2.5 : 4.1 
5 
3.96 (1.167) 
4.74 
2.6 : 4.9 
4 
3.76 
(1.121) 
3.86 
2.5 : 4.8 
1 
5.73 (NC) 
5.73 
5.7 : 5.7 
3 
5.59 
(0.069) 
5.58 
5.5 : 5.7 
23 
16 
1 
3.12 (1.772) 
3.91 (1.957) 
1.48 (NC) 
2.69 
0.4 : 7.8 
3.06 
2.1 : 7.7 
1.48 
1.5 : 1.5 
Distribution of duration on 
olipudase alfa, n (%) 
  >0 to <1 year 
  ≥1 to <2 years 
  ≥2 to <3 years 
  ≥3 to <4 years 
  ≥4 to <5 years 
  ≥5 to <6 years 
  ≥6 to <7 years 
  ≥7 years 
Cumulative distribution of 
duration on olipudase alfa, 
n (%) (patient-years) 
  >0 year 
0 
0 
0 
0 
0 
0 
0 
0 
2 (50.0%) 
1 (25.0%) 
1 (25.0%) 
2 (66.7%) 
2 (40.0%) 
0 
0 
1 (33.3%) 
3 (60.0%) 
1 (25.0%) 
1 (25.0%) 
2 (50.0%) 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1 (100.0%) 
3 (100.0%) 
0 
0 
0 
0 
1 (4.3%) 
5 (21.7%) 
0 
0 
0 
1 
(100.0%) 
7 (30.4%) 
8 (50.0%) 
5 (21.7%) 
4 (25.0%) 
3 (13.0%) 
1 (6.3%) 
0 
0 
0 
0 
2 (8.7%) 
3 (18.8%) 
0 
0 
0 
0 
0 
0 
4 (100.0%) 
(13.43) 
3 (100.0%) 
(9.50) 
5 (100.0%) (
19.82) 
4 
(100.0%) 
(15.06) 
1 (100.0%) 
(5.73) 
3 (100.0%) 
(16.76) 
23 (100.0%) 
(71.78) 
16 (100.0%) 
(62.52) 
0 (0) 
1 
(100.0%) 
(1.48) 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extent of Treatment 
Exposure 
  ≥1 year 
Infant/early child 
(<6 years old)  
Female 
(N = 4) 
4 (100.0%) 
(13.43) 
Male 
(N = 3) 
3 (100.0%) 
(9.50) 
Child (6 to <12 years 
old) 
Female 
(N = 5) 
5 (100.0%) 
(19.82) 
4 (100.0%) 
(13.43) 
3 (100.0%) 
(9.50) 
5 (100.0%) 
(19.82) 
2 (50.0%) 
(8.09) 
1 (25.0%) 
(4.16) 
1 (33.3%) 
(4.14) 
1 (33.3%) 
(4.14) 
3 (60.0%) 
(14.43) 
3 (60.0%) 
(14.43) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
  ≥2 years 
  ≥3 years 
  ≥4 years 
  ≥5 years 
  ≥6 years 
  ≥7 years 
Duration on olipudase alfa in 
initial dose escalation period 
(years) 
Male 
(N = 4) 
4 
(100.0%) 
(15.06) 
4 
(100.0%) 
(15.06) 
3 (75.0%) 
(12.55) 
2 (50.0%) 
(9.41) 
0 (0) 
Adolescent (12 to 
<18 years old) 
Female 
(N = 1) 
1 (100.0%) 
(5.73) 
Male 
(N = 3) 
3 (100.0%) 
(16.76) 
Adult (18 to 
<65 years old) 
Female 
(N = 23) 
22 (95.7%) 
(71.39) 
Male 
(N = 16) 
16 (100.0%) 
(62.52) 
1 (100.0%) 
(5.73) 
3 (100.0%) 
(16.76) 
17 (73.9%) 
(62.46) 
16 (100.0%) 
(62.52) 
Elderly Adult 
(≥65 years old) 
Male 
Female 
(N = 1) 
(N = 0) 
1 
(100.0%) 
(1.48) 
0 (0) 
0 (0) 
0 (0) 
1 (100.0%) 
(5.73) 
1 (100.0%) 
(5.73) 
1 (100.0%) 
(5.73) 
3 (100.0%) 
(16.76) 
3 (100.0%) 
(16.76) 
3 (100.0%) 
(16.76) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
10 (43.5%) 
(45.52) 
5 (21.7%) 
(28.68) 
2 (8.7%) 
(15.57) 
2 (8.7%) 
(15.57) 
2 (8.7%) 
(15.57) 
8 (50.0%) 
(41.32) 
4 (25.0%) 
(27.35) 
3 (18.8%) 
(23.06) 
3 (18.8%) 
(23.06) 
3 (18.8%) 
(23.06) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
  Number of patients with value 
4 
  Mean (SD) 
0.37 (0.111) 
  Median 
0.32 
3 
0.55 
(0.355) 
0.38 
5 
0.37 (0.032) 
0.38 
4 
0.32 
(0.039) 
0.31 
1 
0.31 (NC) 
0.31 
3 
0.32 
(0.022) 
0.31 
23 
16 
1 
0.36 (0.212) 
0.27 (0.020) 
0.27 (NC) 
0.27 
0.27 
0.27 
0 
0 
0 
0.3 : 0.5 
  Min : Max 
0.3 : 1.0 
Percentages are based on the number of safety set in each group.  
Initial dose escalation period is the first time when patient reached the 3 mg/kg; or if a patient never reached 3mg/kg, then the cut would be the first time the patient maintains the maximum tolerated 
dose consecutively for 6 visits.  
Age is determined based on Day 1 of the first olipudase alfa study that a patient participated. 
PGM=PRODOPS/GZ402665/OVERALL/ISS_2021/REPORT/PGM/cdc_expbyss_t.sas OUT=REPORT/OUTPUT/cdc_expbyss_t_age_i.rtf (22JUN2021 - 6:48)  
Max: Maximum; Min: Minimum; N: Number; SD: Standard Deviation. 
0.3 : 0.3 
0.2 : 1.2 
0.2 : 0.3 
0.3 : 0.3 
0.3 : 0.4 
0.3 : 0.4 
0.3 : 0.3 
0 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
For summary of exposure by dose in Table 12, since each study has a dose escalation phase, each patient was summarized into multiple dose 
groups. 
Median duration of exposure to olipudase alfa was low across infusion doses between 0.03 to 2.0 mg/kg (range 0 to 3.1), the doses administered 
during dose escalation, compared to a median of 2.68 years (range 0.1 to 7.6) for the targeted maintenance dose 3.0 mg/kg dose. 
Table 12 - Exposure by dose  
While at Infusion Dose (mg/kg) 
0.03 (N = 20) 
0.1 (N = 60) 
0.3 (N = 60) 
0.6 (N = 60) 
1 (N = 60) 
2 (N = 60) 
3 (N = 59) 
0.75 
2.69 
6.20 
5.89 
6.64 
7.59 
186.32 
Extent of Treatment Exposure 
Cumulative duration of olipudase alfa 
exposure (patient-years) 
Duration on olipudase alfa (years) 
  Number of patients with value 
20 
60 
60 
60 
60 
60 
59 
  Mean (SD) 
  Median 
  Min : Max 
0.04 (0.002) 
0.04 (0.033) 
0.10 (0.074) 
0.10 (0.068) 
0.11 (0.403) 
0.13 (0.249) 
3.16 (1.663) 
0.04 
0.0 : 0.0 
0.04 
0.0 : 0.3 
0.08 
0.1 : 0.6 
0.08 
0.0 : 0.5 
0.04 
0.0 : 3.1 
0.04 
0.0 : 1.4 
2.68 
0.1 : 7.6 
Distribution of duration on olipudase alfa, 
n (%) 
  >0 to <1 year 
  ≥1 to <2 years 
  ≥2 to <3 years 
  ≥3 to<4 years 
  ≥4 to <5 years 
  ≥5 to <6 years 
  ≥6 to <7 years 
  ≥7 years 
20 (100.0%) 
60 (100.0%) 
60 (100.0%) 
60 (100.0%) 
59 (98.3%) 
58 (96.7%) 
1 (1.7%) 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1 (1.7%) 
0 
0 
0 
0 
2 (3.3%) 
0 
0 
0 
0 
0 
0 
13 (22.0%) 
19 (32.2%) 
10 (16.9%) 
8 (13.6%) 
4 (6.8%) 
0 
4 (6.8%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extent of Treatment Exposure 
Cumulative distribution of duration on 
olipudase alfa, n (%) (patient-years) 
  >0 year 
  ≥1 year 
  ≥2 years 
  ≥3 years 
  ≥4 years 
  ≥5 years 
  ≥6 years 
  ≥7 years 
While at Infusion Dose (mg/kg) 
0.03 (N = 20) 
0.1 (N = 60) 
0.3 (N = 60) 
0.6 (N = 60) 
1 (N = 60) 
2 (N = 60) 
3 (N = 59) 
20 (100.0%) (0.75)  60 (100.0%) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
(2.69) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
60 (100.0%) 
(6.20) 
60 (100.0%) 
(5.89) 
60 (100.0%) 
(6.64) 
60 (100.0%) 
(7.59) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
1 (1.7%) (3.14) 
2 (3.3%) (2.55) 
1 (1.7%) (3.14) 
0 (0) 
1 (1.7%) (3.14) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
59 (100.0%) 
(186.32) 
58 (98.3%) 
(186.20) 
45 (76.3%) 
(166.24) 
26 (44.1%) 
(119.97) 
16 (27.1%) 
(85.45) 
8 (13.6%) 
(51.07) 
4 (6.8%) 
(29.85) 
4 (6.8%) 
(29.85) 
Percentages are based on the number of safety set in each group. 
The duration of exposure is the duration while patients are at that dose level. 
PGM=PRODOPS/GZ402665/OVERALL/ISS_2021/REPORT/PGM/cdc_expbyss1_t.sas OUT=REPORT/OUTPUT/cdc_expbyss1_t_inf_overall_i.rtf (22JUN2021 - 6:48)  
Max: Maximum; Min: Minimum; N: Number; SD: Standard Deviation. 
 
 
  
  
  
 
 
 
 
Table 13 - Exposure by ethnic origin  
Extent of Treatment Exposure 
Hispanic (N = 12)  Non-Hispanic (N = 46) 
Cumulative duration of olipudase alfa exposure (patient-years) 
32.59 
172.85 
Duration on olipudase alfa (years) 
  Number of patients with value 
  Mean (SD) 
  Median 
  Min : Max 
Distribution of duration on olipudase alfa, n (%) 
  >0 to <1 year 
  ≥1 to <2 years 
  ≥2 to <3 years 
  ≥3 to <4 years 
  ≥4 to <5 years 
  ≥5 to <6 years 
  ≥6 to <7 years 
  ≥7 years 
Cumulative distribution of duration on olipudase alfa, n (%) 
(patient-years) 
  >0 year 
  ≥1 year 
  ≥2 years 
  ≥3 years 
  ≥4 years 
  ≥5 years 
  ≥6 years 
  ≥7 years 
12 
46 
2.72 (0.766) 
3.76 (1.729) 
2.84 
1.7 : 4.2 
3.38 
0.4 : 7.8 
0 
3 (25.0%) 
6 (50.0%) 
2 (16.7%) 
1 (8.3%) 
0 
0 
0 
1 (2.2%) 
3 (6.5%) 
15 (32.6%) 
9 (19.6%) 
10 (21.7%) 
4 (8.7%) 
0 
4 (8.7%) 
12 (100.0%) (32.59) 
46 (100.0%) (172.85) 
12 (100.0%) (32.59) 
45 (97.8%) (172.46) 
9 (75.0%) (27.12) 
42 (91.3%) (167.51) 
3 (25.0%) (11.04) 
27 (58.7%) (129.85) 
1 (8.3%) (4.16) 
18 (39.1%) (98.86) 
0 (0) 
0 (0) 
0 (0) 
8 (17.4%) (53.47) 
4 (8.7%) (30.98) 
4 (8.7%) (30.98) 
Duration on olipudase alfa in initial dose escalation period 
(years) 
  Number of patients with value 
12 
46 
  Mean (SD) 
0.31 (0.091) 
0.35 (0.177) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extent of Treatment Exposure 
Hispanic (N = 12)  Non-Hispanic (N = 46) 
  Median 
0.27 
0.31 
0.3 : 0.5 
  Min : Max 
Percentages are based on the number of safety set in each group. 
Initial dose escalation period is the first time when patient reached the 3mg/kg; or if a patient never reached 3 mg/kg, then the cut would 
be the first time the patient maintains the maximum tolerated dose consecutively for 6 visits.  
All ethnicity groups considered include Hispanic or Latino (Hispanic), Not Hispanic or Latino (Not Hispanic), Not Reported, and 
Unknown.  
Two adults had ethnicity “not reported” or “unknown”. 
PGM=PRODOPS/GZ402665/OVERALL/ISS_2021/REPORT/PGM/cdc_expbyss_t.sas 
OUT=REPORT/OUTPUT/cdc_expbyss_t_ethnicity_i.rtf (22JUN2021 - 6:48) 
Max: Maximum; Min: Minimum; N: Number; SD: Standard Deviation. 
0.2 : 1.2 
Table 14 shows exposure by race. Overall, most of the patients were white (n = 53, 88.3%). 
Table 14 - Exposure by race  
Extent of Treatment 
Exposure 
White 
(N = 53) 
Southeast 
Asian (N = 2) 
Northeast 
Asian (N = 2) 
Other (N = 3) 
Cumulative duration of olipudase 
alfa exposure (patient-years) 
Duration on olipudase alfa (years) 
189.53 
10.51 
6.07 
9.97 
  Number of patients with value 
53 
2 
2 
3 
  Mean (SD) 
  Median 
  Min : Max 
3.58 (1.737) 
5.25 (0.678) 
3.03 (0.637) 
3.32 (1.463) 
3.10 
5.25 
0.4 : 7.8 
4.8 : 5.7 
3.03 
2.6 : 3.5 
2.99 
2.1 : 4.9 
Distribution of duration on olipudase 
alfa, n (%) 
  >0 to <1 year 
  ≥1 to <2 years 
  ≥2 to <3 years 
  ≥3 to <4 years 
  ≥4 to <5 years 
  ≥5 to <6 years 
  ≥6 to <7 years 
  ≥7 years 
1 (1.9%) 
6 (11.3%) 
19 (35.8%) 
10 (18.9%) 
9 (17.0%) 
3 (5.7%) 
0 
5 (9.4%) 
0 
0 
0 
0 
1 (50.0%) 
1 (50.0%) 
0 
0 
0 
0 
1 (50.0%) 
1 (50.0%) 
0 
0 
0 
0 
0 
0 
2 (66.7%) 
0 
1 (33.3%) 
0 
0 
0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extent of Treatment 
Exposure 
White 
(N = 53) 
Southeast 
Asian (N = 2) 
Northeast 
Asian (N = 2) 
Other (N = 3) 
Cumulative distribution of duration 
on olipudase alfa, n (%) 
(patient-years) 
  >0 year 
  ≥1 year 
  ≥2 years 
  ≥3 years 
  ≥4 years 
  ≥5 years 
  ≥6 years 
  ≥7 years 
53 (100.0%) 
(189.53) 
52 (98.1%) 
(189.14) 
46 (86.8%) 
(178.73) 
27 (50.9%) 
(129.62) 
17 (32.1%) 
(95.23) 
8 (15.1%) 
(55.38) 
5 (9.4%) 
(38.63) 
5 (9.4%) 
(38.63) 
2 (100.0%) (10.51) 
2 (100.0%) (6.07) 
3 (100.0%) (9.97) 
2 (100.0%) (10.51) 
2 (100.0%) (6.07) 
3 (100.0%) (9.97) 
2 (100.0%) (10.51) 
2 (100.0%) (6.07) 
3 (100.0%) (9.97) 
2 (100.0%) (10.51) 
1 (50.0%) (3.49) 
1 (33.3%) (4.92) 
2 (100.0%) (10.51) 
0 (0) 
1 (33.3%) (4.92) 
1 (50.0%) (5.73) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
Duration on olipudase alfa in initial 
dose escalation period (years) 
  Number of patients with value 
53 
2 
2 
3 
  Mean (SD) 
  Median 
0.34 (0.170) 
0.33 (0.027) 
0.27 (0.002) 
0.30 (0.063) 
0.30 
0.33 
0.27 
0.27 
0.2 : 1.2 
0.3 : 0.3 
  Min : Max 
Percentages are based on the number of safety set in each group.  
Initial dose escalation period is the first time when patient reached the 3 mg/kg; or if a patient never reached 3 mg/kg, then the cut would 
be the first time the patient maintains the maximum tolerated dose consecutively for 6 visits. 
Only race groups with patients are included in the table.  
All race groups considered include American Indian or Alaska Native, Black, Native Hawaiian or Other Pacific Islander, White, South 
East Asian, North East Asian, Not Reported, Unknown and Other.  
PGM=PRODOPS/GZ402665/OVERALL/ISS_2021/REPORT/PGM/cdc_expbyss_t.sas 
OUT=REPORT/OUTPUT/cdc_expbyss_t_race_i.rtf (22JUN2021 - 6:48)  
Max: Maximum; Min: Minimum; N: Number; SD: Standard Deviation. 
0.3 : 0.4 
0.3 : 0.3 
Table 15 shows exposure by baseline cirrhosis. Because of the significant prevalence of cirrhosis in 
patients with ASMD, patients with baseline cirrhosis were chosen to be an intrinsic factor for 
analysis. There were 3 of 40 olipudase alfa-treated adult patients who had cirrhosis at baseline. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 15 - Exposure by baseline cirrhosis  
Extent of Treatment Exposure 
Having Baseline 
Cirrhosis (N = 3) 
Not having Baseline 
Cirrhosis (N = 57) 
Cumulative duration of olipudase alfa exposure 
(patient-years) 
4.34 
211.74 
Duration on olipudase alfa (years) 
  Number of patients with value 
  Mean (SD) 
  Median 
  Min : Max 
Distribution of duration on olipudase alfa, n (%) 
  >0 to < 1 year 
  ≥1 to <2 years 
  ≥2 to <3 years 
  ≥3 to <4 years 
  ≥4 to <5 years 
  ≥5 to <6 years 
  ≥6 to <7 years 
  ≥7 years 
Cumulative distribution of duration on olipudase 
alfa, n (%) (patient-years) 
3 
1.45 (1.044) 
1.48 
0.4 : 2.5 
1 (33.3%) 
1 (33.3%) 
1 (33.3%) 
0 
0 
0 
0 
0 
57 
3.71 (1.645) 
3.14 
1.7 : 7.8 
0 
5 (8.8%) 
21 (36.8%) 
11 (19.3%) 
11 (19.3%) 
4 (7.0%) 
0 
5 (8.8%) 
  >0 year 
  ≥1 year 
  ≥2 years 
  ≥3 years 
  ≥4 years 
  ≥5 years 
  ≥6 years 
  ≥7 years 
3 (100.0%) (4.34) 
57 (100.0%) (211.74) 
2 (66.7%) (3.95) 
1 (33.3%) (2.47) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
57 (100.0%) (211.74) 
52 (91.2%) (202.80) 
31 (54.4%) (148.54) 
20 (35.1%) (110.66) 
9 (15.8%) (61.12) 
5 (8.8%) (38.63) 
5 (8.8%) (38.63) 
Duration on olipudase alfa in initial dose escalation 
period (years) 
  Number of patients with value 
3 
57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extent of Treatment Exposure 
Having Baseline 
Cirrhosis (N = 3) 
Not having Baseline 
Cirrhosis (N = 57) 
  Mean (SD) 
  Median 
0.57 (0.531) 
0.27 
0.33 (0.118) 
0.30 
0.3 : 1.2 
  Min : Max 
Percentages are based on the number of safety set in each group.  
Initial dose escalation period is the first time when patient reached the 3mg/kg; or if a patient never reached 3mg/kg, then the cut would 
be the first time the patient maintains the maximum tolerated dose consecutively for 6 visits.  
PGM=PRODOPS/GZ402665/OVERALL/ISS_2021/REPORT/PGM/cdc_expbyss_t.sas OUT=REPORT/OUTPUT/cdc_expbyss_t_cirr_i.rtf 
(22JUN2021 - 6:48) 
Max: Maximum; Min: Minimum; N: Number; SD: Standard Deviation. 
0.2 : 1.0 
 
RISK MANAGEMENT PLAN - PART II MODULE SIV: POPULATIONS NOT 
STUDIED IN CLINICAL TRIALS  
SIV.1 
EXCLUSION CRITERIA IN PIVOTAL CLINICAL STUDIES WITHIN THE 
DEVELOPMENT PROGRAMME  
Table 16 - Important exclusion criteria in pivotal studies in the development program  
Exclusion criteria 
Reason for exclusion 
Rationale 
Is it considered 
to be included 
as missing 
information? 
Pregnant women 
To avoid potential harm to an 
unborn fetus through exposure 
of drug. 
No 
In animal studies, 
reproductive toxicity was 
observed.  
“Foetal toxicity” is 
considered as an 
important potential risk. 
Not applicable 
Olipudase alfa exposure 
in patients who have had 
a major organ transplant 
does not constitute an 
additional safety concern.  
Olipudase alfa exposure 
in patients having these 
medical conditions does 
not constitute an 
additional safety concern. 
Yes 
No 
No 
To avoid potential harm to a 
newborn through exposure of 
drug from breast milk. 
Patients with organ transplants 
have maintenance medications 
and comorbidities that would 
confound the evaluation of the 
safety profile of olipudase alfa. 
Patients with serious 
inter-current illnesses were 
excluded from the study due to 
the possibility that it may 
significantly interfere with study 
compliance including all 
prescribed evaluations and 
follow-up activity, and 
measurement of safety 
(bleeding) and efficacy 
endpoints (improved platelet 
count). 
Lactating women 
Patient had major organ transplant 
(eg, bone marrow or liver) 
Patient has a medical condition, 
including serious inter-current 
illness, active hepatitis B or C or 
HIV infection, INR >1.5, platelet 
count <60.0x103/μL, significant 
cardiac disease (eg, pulmonary 
artery pressure >40 mm Hg, 
moderate or severe valvular 
dysfunction, or <40% left 
ventricular ejection fraction by 
ECHO), or any other extenuating 
circumstance that may 
significantly interfere with study 
compliance including all 
prescribed evaluations and 
follow-up activities. 
Clinical presentation or genetic 
defects in the pediatric population 
suggestive of ASMD type A 
disease. 
No  
The rapid neurologic 
progression and early death 
would confound the evaluation 
of the safety profile of 
olipudase alfa. 
Olipudase alfa will be not 
indicated in ASMD type A 
patients.  
 
Exclusion criteria 
Reason for exclusion 
Rationale 
Is it considered 
to be included 
as missing 
information? 
Patient with a total splenectomy. 
The patient is scheduled during 
the study for in-patient 
hospitalization including elective 
surgery and excluding the liver 
biopsies required per protocol 
(Specific to DFI13803 and 
DFI12712). 
Concomitant ingestion of several 
classes of medications (eg, 
fluoxetine, chlorpromazine, 
tricyclic antidepressants [eg, 
imipramine, or desipramine], 
cationic amphiphilic antihistamines 
[eg, loratadine, desloratadine, 
astemizole, ebastine and 
clemastine]). 
No 
Reduction in spleen size was a 
key efficacy endpoint in 
previous clinical studies, which 
could not be evaluated in 
splenectomized patients. 
Elective surgeries may interfere 
with the patient’s compliance 
with study visit schedule. 
No 
No 
Based on the available 
publications of in vitro and in 
silico data, ASM activity may be 
decreased in patients due to 
concomitant ingestion of certain 
selected cationic amphiphilic 
drugs (tricyclic antidepressants, 
SSRIs, and antihistamines). 
(34) Efficacy assessments 
could be impaired by these 
medications. 
Olipudase alfa exposure 
in patients who have had 
a splenectomy does not 
constitute an additional 
safety concern. 
Excluded for study 
operational and not for 
safety reasons. 
The clinical relevance of 
this theoretical interaction 
with FIASMAs is 
unknown. 
(Section SVII.1). 
ASM: Acid Sphingomyelinase; ASMD: Acid Sphingomyelinase Deficiency; ECHO: Echocardiography; FIASMA: Functional Inhibitors of 
Acid Sphingomyelinase; HIV: Human Immunodeficiency Virus; INR: International Normalized Ratio; SSRI: Selective Serotonin Reuptake 
Inhibitor. 
SIV.2 
LIMITATIONS TO DETECT ADVERSE REACTIONS IN CLINICAL TRIAL 
DEVELOPMENT PROGRAMMES  
The clinical development program is unlikely to detect rare or very rare adverse reactions due to the 
small number of patients (n = 66). 
SIV.3 
LIMITATIONS IN RESPECT TO POPULATIONS TYPICALLY 
UNDER-REPRESENTED IN CLINICAL TRIAL DEVELOPMENT PROGRAMMES  
Table 17 - Exposure of special populations included or not in clinical trial development program  
Type of special population 
Exposure 
Pregnant women 
Lactating women 
Not included in the clinical development program.  
Data available from animal studies only.  
Patients with relevant comorbidities: 
Patients identified with cirrhosis (ie, >stage 3 
fibrosis on liver biopsy) 
Although initially excluded, DFI12712 ASCEND was amended to 
allow including patients with cirrhosis. Three patients (5.12%) in 
adult safety population were cirrhotic at baseline in clinical studies. 
 
Type of special population 
Exposure 
Patients with ASMD type A 
Populations with relevant different ethnic origin and 
different races 
Patients using the following classes of medications 
(eg, fluoxetine, chlorpromazine, tricyclic 
antidepressants [eg, imipramine, or desipramine], 
cationic amphiphilic antihistamines [eg, loratadine, 
desloratadine, astemizole, ebastine and 
clemastine]). 
Not included in the clinical development program. One patient with 
ASMD type A, via an emergency IND, outside of the clinical 
development program has been treated with olipudase alfa. 
Clinical development program not enriched for specific populations.  
No drug interaction studies have been performed. Patients using 
these medications were not included in the clinical development 
program. 
ASMD: Acid Sphingomyelinase Deficiency; IND: Investigational New Drug. 
Pregnant women  
There are no data from the use of olipudase alfa in pregnant women. In study DFI12712, there was 
one pregnancy in a partner of a patient exposed to olipudase alfa. The partner gave birth to a 
 at week 38 of gestation by c-section and no congenital anomaly was 
child 
reported. The child was breastfeeding soon after birth with no neonatal illness, need for 
resuscitation or corrective or intensive care treatment.  
Studies in animals have shown reproductive toxicity. An increased incidence of exencephaly was 
observed in a single species (mice) at exposure less than the human exposure at the recommended 
maintenance therapeutic dose and frequency; the relevance of this observation for humans is 
unknown. It is not recommended during pregnancy and in women of child bearing potential 
(WOCBP) not using effective contraception, unless the potential benefits to the mother outweigh 
the potential risks, including those to the foetus (see [Module part II SII] Table 7). 
Pregnant women are part of the target population. Therefore, “foetal toxicity” is considered as 
important potential risk (see Section SVII.1.1). 
Lactating women 
There are no data available concerning the use of olipudase alfa in lactating women.  
Lactating women are part of the target population. Therefore, the use of olipudase alfa in lactating 
women is considered as missing information (see Section SVII.1.1). 
Patients with relevant comorbidities 
Hepatic cirrhosis is a known complication of ASMD. Cirrhosis was initially an exclusion criterion 
in DFI1712 ASCEND. The protocol was subsequently amended to allow the inclusion of ASMD 
patients with cirrhosis. There have been 3 patients with stage 3 cirrhosis enrolled in the clinical 
development program. Although data are limited, the tolerability of olipudase alfa in patient with 
cirrhosis is consistent with the entire ASMD adult population. 
Populations with relevant different ethnic origin and different race 
To date, there is no information to suggest that patients with any specific racial or ethnic origins are 
differentially affected by olipudase alfa. 
 
 
Patient with ASMD Type A 
Olipudase alfa does not cross the blood brain barrier and is not expected to treat the CNS 
manifestations of the disease. 
Patient taking several classes of medications 
Based on the available publications of in vitro and in silico data, ASM activity may be decreased in 
patients due to concomitant ingestion of certain classes of medications with cationic amphiphilic 
structures including antihistamines and antidepressants. (34)(35) The clinical relevance of this 
theoretical interaction is unknown. 
Drug-drug interactions (DDI) are routinely monitored as part of routine pharmacovigilance activity. 
It is not considered relevant for the RMP (see Section SVII.1.1).
 
RISK MANAGEMENT PLAN - PART II MODULE SV: 
POST-AUTHORIZATION EXPERIENCE  
The marketing authorization holder (MAH) is currently utilizing the Margin 
Consolidated (MARCO) application for reporting of sales data from postmarketing experience and 
has been doing so since December 2019.  
As World Health Organization (WHO) defined daily dose (DDD) for parenteral formulation is not 
available, the patient exposure in patient years (PYs) could not be estimated for infusion powder, 
injection liquid (solution)1 and injection. 
Sales from the cumulative experience is available from MARCO for the period from 01 May 2020 
through 30 September 2022.  
A total of 83 vials of infusion powder, 2914 vials of injection liquid (solution) and 2202 vials of 
injection powder were sold worldwide during the cumulative period. 
Detailed usage data are not available therefore presentation of sales data by age, sex, and indication 
is not possible. Consequently, it is only presented by country and formulation: 
 Table 18   Olipudase alfa worldwide sales - Sanofi (01 May 2020 to 30 September 2022a) in units  
COUNTRY 
OLIPUDASE ALFA 
INFUSION POWDER 
INJECTION LIQUID (SOLUTION)  
INJECTION POWDER 
20 mg/5 mL  
20 mg/1 mL 
20 mg/5 mL 
Grand Total 
83 
2914 
2202 
UNITS: 
INFUSION, POWDER/INJECTION, LIQUID (SOLUTION)/INJECTION, POWDER: Total number of Vials. 
SOURCE: MARCO database updated (13-OCT-2022). 
a  Sales data is available from May-2020 in Marco database. 
MARCO: Margin Consolidated; US: United States. 
1 Injection, liquid (solution) should be considered as infusion, powder (data entry error). This formulation 
concerns free goods for hospitals. 
 
 
                                                 
RISK MANAGEMENT PLAN - PART II MODULE SVI: ADDITIONAL EU 
REQUIREMENTS FOR THE SAFETY SPECIFICATION  
SVI.1 
POTENTIAL FOR MISUSE FOR ILLEGAL PURPOSES  
The properties of olipudase alfa do not indicate a potential for misuse for illegal purposes. 
A drug abuse liability assessment (DALA) study was not performed with olipudase alfa as the 
protein has no ability to cross the blood-brain barrier with negligible exposure in the brain, and has 
shown no propensity for eliciting any neurological effects in toxicology studies. 
The company medical query (CMQ) related to drug abuse and associated liabilities was used to 
identify relevant treatment emergent adverse event (TEAEs). During the double-blind PAP of 
DFI12712, preferred terms (PT) related to drug abuse and associated liabilities were reported more 
frequently in the placebo group, compared to the olipudase alfa treatment group and included 
anxiety (16.7% and 0%, respectively) and dizziness (11.1% and 0%). The PT of feeling abnormal 
was reported by 1 (5.6%) patient in the olipudase alfa group. 
The most frequently observed PTs in the overall population (>20% of patients) were headache, 
pyrexia, nausea, abdominal pain, diarrhea, vomiting, myalgia, fatigue, dizziness and rhinorrhoea. 
The potential for misuse of olipudase alfa for illegal purposes is considered low as this product has 
not been shown to have known pharmacological addictive effects, such as intentional overdose, 
abuse, or illegal use. 
Routine pharmacovigilance activities thus, are considered sufficient to monitor a potential for 
misuse for illegal purposes related to olipudase alfa. 
 
RISK MANAGEMENT PLAN - PART II MODULE SVII: IDENTIFIED AND 
POTENTIAL RISKS   
SVII.1 
IDENTIFICATION OF SAFETY CONCERNS IN THE INITIAL RMP SUBMISSION  
The following safety topics were assessed as either not relevant to olipudase alfa RMP based on the 
currently available clinical evidence or not benefiting from additional pharmacovigilance or 
additional risk minimization activities. 
The safety topics, evaluated in Section SVII.1.1 as not important for inclusion in the list of safety 
concerns in the RMP, are the following:  
•  Lack of efficacy due to neutralizing antidrug antibody (ADA) 
•  Reduced efficacy of olipudase alfa due to ASM inhibition in context of PD DDI 
•  Potential harm from overdose 
•  Potential for transmission of infectious agents 
•  Potential for off-label use 
•  Effect on fertility 
•  Use in pediatric patients 
The following safety topics were considered important for inclusion in the list of safety concerns in 
the initial RMP. They are discussed in Section SVII.1.2: 
Important identified risk: 
• 
Immunogenicity: 
- 
Infusion associated reactions (IARs), 
-  Systemic hypersensitivity including anaphylactic reactions, 
-  Anti-Drug Antibody (ADA) mediated hypersensitivity reactions, 
Important potential risks: 
•  Medication errors in home infusion setting 
•  Foetal toxicity 
Missing information: 
•  Use in lactating women  
•  Long-term safety (beyond 2 years) 
 
SVII.1.1  Risks not considered important for inclusion in the list of safety 
concerns in the RMP  
Reason(s) for not including an identified or potential risk in the list of safety concerns in the 
RMP 
Risks known to be associated with other therapeutic ERTs, but assessed as not relevant to 
olipudase alfa and its benefit-risk balance, based on the currently available evidence or which 
would not benefit from additional risk minimization activities or from further evaluation: 
•  Lack of efficacy due to Neutralizing antibodies: 
There has been no evidence throughout the clinical development program for olipudase alfa that 
detection of in vitro neutralizing antibodies (NAb) is associated with lack of efficacy. 
Neutralizing antibodies are a subset of binding ADAs that bind to the drug and inhibit its 
pharmacological function by preventing target binding and biologic activity of the drug. 
Patients were initially screened for development of ADA and confirmed ADA positive samples 
were further evaluated for the presence of NAb that could inhibit enzymatic activity or uptake into 
cells. (36) Overall, 9 of 60 patients (15%) developed NAb that inhibited olipudase alfa catalytic 
activity. Three (3) patients had a persistent response that was intermittent, and 6 patients had a 
transient response which was NAb-positive at only one timepoint that reverted to NAb-negative. 
There were no patients who developed NAb that inhibited cellular uptake. Overall, the development 
of NAb, did not have a meaningful effect on PK, PD (plasma lyso-sphingomyelin), safety and 
efficacy parameters in these patients including the 3 patients with persistent NAb. 
Given the totality of the data, “Lack of efficacy due to NAb” is not considered as an important 
potential risk in the RMP. Routine pharmacovigilance should suffice to address and monitor 
potential lack of efficacy. 
Other reasons for considering the risks not important for inclusion in the RMP: 
•  Lack of efficacy due to acid sphingomyelinase inhibition in context of 
pharmacodynamic drug-drug interaction 
Based on the available publications of in vitro and in silico data, ASM activity may be decreased in 
patients due to concomitant use of FIASMAs. Functional inhibitors of acid sphingomyelinase are a 
large group of cationic amphiphilic molecules that may disrupt ASM interaction with the lysosomal 
membrane and are found in certain classes of medications, including tricyclic antidepressants and 
some anti-histamines. The clinical relevance of this theoretical functional inhibition is not known. 
A non-clinical PD drug interaction study (Study 19-01094) was conducted in ASMKO mice that 
suggested that fluoxetine and citalopram may not affect SM clearance following a single 
administration of 1 mg/kg olipudase alfa. Co-administration of olipudase alfa with 
fluoxetine (300 µg/day) or citalopram (192 µg/day) had no effect on olipudase alfa-mediated SM 
reduction in the liver and spleen, but the circulating levels of fluoxetine and citalopram were in the 
lower end of the therapeutic window for each drug. The possibility of reduced efficacy of olipudase 
alfa due to ASM inhibition in the context of PD DDI cannot be excluded. 
 
These concomitant medications were prohibited during the clinical development program; thus, 
there are no data to confirm the findings from the study in ASKMO mice, nor have any DDIs been 
reported. The clinical relevance of this DDI risk with FIASMAs remains unclear but is likely low. 
Therefore, if patients need to use these concomitant medications, the benefit-risk profile would 
remain favorable considering the severity of the disease and the limited treatments available. 
The risk is not considered as an important risk for the RMP.  
•  Potential harm from overdose: 
No instance of asymptomatic or symptomatic overdose has been observed in clinical studies during 
the dose escalation or the maintenance periods. Highest dose tested in preclinical studies was a 
NOAEL. Dose escalation regimen are described in the summary of product characteristics (SmPC) 
for adult and pediatric patients. 
•  Potential for transmission of infectious agents: 
The potential for transmission of an infectious agent by olipudase alfa is considered very low based 
upon the following: 
-  No human-derived material is used during the manufacturing process; 
-  Animal derived material used during the manufacturing process complies with the 
current Committee for Human Medicinal Products, Note for Guidance, entitled 
“Minimizing the Risk of Transmitting Animal Spongiform Encephalopathic Agents via 
Human and Veterinary Medicinal Products”; 
-  Animal serum used during the manufacturing process is irradiated to mitigate the risk of 
adventitious virus contamination; 
-  There is robust virus reducing capacity during the product purification process; total 
reduction factors vary from ≥5.7 log to ≥15.9 log for the four-model virus tested. The 
process includes a 20 nm filter which is robust and completely removed all model 
viruses tested, including demonstrated clearance of ≥5.8 log of mouse minute virus (the 
smaller virus tested); 
-  Characterization testing has confirmed the absence of infectious adventitious and 
endogenous agents in the Master Cell Bank, Working Cell Bank, and End of Production 
cells; 
- 
In the event of suspected or confirmed transmission of infectious agents or other 
contamination, pharmacovigilance will perform an assessment of the risk to patient 
safety. 
Other concerns not considered important for inclusion in the RMP: 
•  Effect on fertility: 
Administration of olipudase alfa had no effects on mating and fertility of the male or female mice 
or litter parameters of female mice and rabbits evaluated at mid-gestation (NOAELs 
were 30 mg/kg, highest dose evaluated). 
 
•  Potential for off-label use: 
According to current knowledge, it is unlikely that this drug will be prescribed for any other 
indication than ASMD. 
•  Use in pediatric patients: 
The safety and efficacy of olipudase alfa was studied in pediatric population (patients were eligible 
from birth to <18 years) as part of the target population. With the exception of the higher 
frequency of treatment emergent infusion associated reactions in pediatric patients, which were 
manageable and did not preclude continuation of treatment, the safety and efficacy profile of 
treatment with olipudase alfa in pediatric patients was found to be consistent with that seen in 
adults. 
SVII.1.2  Risks considered important for inclusion in the list of safety concerns in the RMP  
Table 19 - Important identified risk considered for inclusion in the list of safety concerns: 
Immunogenicity: Infusion associated reactions (IARs), systemic hypersensitivity including 
anaphylactic reactions, ADA mediated hypersensitivity reactions  
Immunogenicity: Infusion associated reactions (IARs), systemic hypersensitivity including 
anaphylactic reactions, ADA mediated hypersensitivity reactions 
Scientific evidence that 
has led to the inclusion 
Clinical trial experience:  
•  Infusion associated reactions have been observed in all studies in the olipudase alfa 
clinical development program; 58.3% of patients in the overall safety population had at 
least one protocol defined infusion associated reaction. 
•  Systemic hypersensitivity including anaphylactic reactions; antibody-mediated 
hypersensitivity reactions with positive IgG and/or IgE ADA have been observed in the 
clinical program (phase 1/2 trial DFI13803 in pediatric patients, repeat-dose 1b trial 
DFI13412 in adult patients).  
•  One pediatric patient had one event of anaphylaxis and another pediatric patient had three 
events of hypersensitivity. Both pediatric patients were ADA positive, however, both 
patients recovered and continued in the study including the long-term extension. 
•  The clinical findings support that olipudase alfa has a low immunogenicity risk relative to 
ADA impact on clinical outcomes. A higher incidence of treatment emergent IARs and 
hypersensitivity was seen in patients who developed treatment emergent ADA versus 
those who did not; however, the IARs were manageable and did not preclude continuation 
of treatment. 
 with ASMD type A, was treated under an emergency 
Other:  
One pediatric patient, 
IND, extrinsic to the clinical development program. This patient experienced two anaphylactic 
reactions (see 5.3.5.4 Investigator initiated emergency IND report). 
Class effects: 
The potential of developing an IAR is reported in the product information of some marketed 
ERTs, including FABRAZYME®, MYOZYME®, CEREZYME®, NAGLAZYME®. 
Scientific literature: 
Olipudase alfa contains trace amounts of polysorbate 80 (<0.02% by weight). 
Hypersensitivity reactions (generalized pruritus, erythema, and orofacial angioedema) to 
polysorbate have been reported rarely in the literature with polysorbate 80 concentrations as 
low as 0.0015%. (37) 
 
Immunogenicity: Infusion associated reactions (IARs), systemic hypersensitivity including 
anaphylactic reactions, ADA mediated hypersensitivity reactions 
Risk-benefit impact 
Although IARs, severe hypersensitivity reactions and ADA mediated hypersensitivity 
reactions may occur with olipudase alfa, the benefit-risk profile of olipudase alfa remains 
favorable. The clinical findings support that olipudase alfa has a low immunogenicity risk 
relative to ADA impact on clinical outcomes. 
ADA: Anti-Drug Antibody; ASMD: Acid Sphingomyelinase Deficiency; ERT: Enzyme Replacement Therapy; IAR: Infusion Associated 
Reaction; IgE: Immunoglobulin E; IgG: Immunoglobulin G; IND: Investigational New Drug. 
Table 20 - Important potential risk considered for inclusion in the list of safety concerns: Medication 
errors in home infusion setting  
Medication errors in home infusion setting 
Scientific evidence that 
has led to the inclusion 
There is potential for human error with respect to administration of the product (eg, dose 
calculation, reconstitution, underdose/overdose, etc.) in the home infusion setting. 
Potential medication error is listed as an important potential risk in the RMP of other 
marketed ERTs for which home infusion setting is possible.  
Clinical trial experience:  
No medication errors have been identified in home infusion setting by the time of data cutoff. 
Risk-benefit impact 
Although the possibility of medication errors cannot be excluded, home infusion is considered 
safe and feasible for patients once selected by the prescribing/treating physician and the 
benefit-risk profile of olipudase alfa is expected to remain favorable in this setting. 
ERT: Enzyme Replacement Therapy; RMP: Risk Management Plan.  
Table 21 - Important potential risk considered for inclusion in the list of safety concerns: Foetal 
toxicity  
Foetal toxicity 
Scientific evidence that 
has led to the inclusion 
Preclinical data:  
In studies in animals, reproductive toxicity was observed. 
An increased incidence of exencephaly was observed when pregnant mice were treated daily 
with olipudase alfa intravenously at exposures levels comparable to the human exposure at 
the recommended maintenance therapeutic dose and frequency. This incidence was slightly 
higher than historical control data. The relevance of this observation for humans is unknown. 
The daily IV administration of olipudase alfa to pregnant rabbits did not result in foetal 
malformations or variations at exposures significantly exceeding the human exposure at the 
recommended maintenance therapeutic dose and frequency. 
Risk-benefit impact 
Patients with ASMD are treated throughout their lifespan and, therefore, may include 
WOCBP. Additional data are needed to characterize the safety profile in this population. 
ASMD: Acid Sphingomyelinase Deficiency; IV: Intravenous; WOCBP: Women of Childbearing Potential. 
Table 22 - Missing information considered for inclusion in the list of safety concerns: Use in lactating 
women  
Use in lactating women 
Scientific rationale for 
anticipating a different 
safety profile in the 
particular subpopulation 
Acid sphingomyelinase deficiency patients are treated throughout their lifespan and, 
therefore, may include lactating women. Non-clinical data do not suggest adverse effects on 
growth and development of nursing pups. 
 
Use in lactating women 
Risk-benefit impact 
Olipudase alfa should be used during lactation only if the potential benefits to the mother 
outweigh the potential risks for the newborn. The benefit-risk profile of olipudase alfa is 
expected to remain favorable in this population. 
Table 23 - Missing information considered for inclusion in the list of safety concerns: Long-term 
safety (beyond 2 years)  
Long-term safety (beyond 2 years) 
Scientific rationale for 
anticipating a different 
safety profile in the 
particular subpopulation 
Risk-benefit impact 
Acid sphingomyelinase deficiency patients are treated throughout their lifespan. 
The benefit-risk profile of olipudase alfa is expected to remain favorable in ASMD patients 
exposed to olipudase alfa for more than 2 years. 
Long-term use safety data beyond 2 years in ASMD patients will be collected through the 
ongoing studies LTS13632 in adults and pediatric patients and DFI12712 ASCEND ETP in 
adult patients. Patients currently enrolled in the clinical studies are expected to continue 
treatment with commercial product and will be monitored through routine pharmacovigilance. 
ASMD: Acid Sphingomyelinase Deficiency; ETP: Extension Treatment Period. 
SVII.2 
NEW SAFETY CONCERNS AND RECLASSIFICATION WITH A SUBMISSION OF 
AN UPDATED RMP  
No new safety concerns or reclassification have been considered since the last RMP approved 
version. 
SVII.3 
DETAILS OF IMPORTANT IDENTIFIED RISKS, IMPORTANT POTENTIAL RISKS, 
AND MISSING INFORMATION  
The following risks have been identified as relevant for inclusion in olipudase alfa RMP: 
• 
Important identified risk: 
- 
Immunogenicity: 
- 
Infusion associated reactions (IARs), 
-  Systemic hypersensitivity including anaphylactic reactions, 
-  Anti-drug Antibody (ADA) mediated hypersensitivity reactions, 
• 
Important potential risks:  
-  Medication errors in home infusion setting 
-  Foetal toxicity 
•  Missing Information: 
-  Use in lactating women 
-  Long-term safety (beyond 2 years) 
 
 
SVII.3.1  Presentation of important identified risks and important potential risks  
 Table 24   Important identified risk: Immunogenicity: Infusion associated reactions (IARs), systemic 
hypersensitivity including anaphylactic reactions, ADA mediated hypersensitivity reactions  
Important identified 
Risk 
Immunogenicity: Infusion associated reactions (IARs), systemic 
hypersensitivity including anaphylactic reactions, ADA mediated 
hypersensitivity reactions 
Potential mechanism 
•  As with other ERTs, IARs are expected. 
•  Hypersensitivity reactions are possible and expected with most subcutaneous or IV 
Evidence source(s) and 
strength of evidence 
administered protein products. 
•  Immunoglobulin G and/or IgE ADA mediated immune response is possible. 
Clinical trial experience, class effects, scientific literature, other (eIND). 
Characterization of the risk  Details of the events related to the sub-types and their impact on patient’s treatment and 
outcome are presented below: 
Frequency: 
In the clinical studies  
•  Infusion associated reactions have been observed in all studies in the olipudase alfa 
clinical development program; 58.3% of patients in the overall safety population had at 
least one protocol defined IAR. 
•  One pediatric patient (5.0%, 1/20 patients) experienced a serious anaphylactic reaction 
in the clinical trial program and was determined to have IgG and IgE antiolipudase 
alfa antibodies. There were two pediatric patients (10.0%) who were positive for IgG 
antiolipudase alfa antibodies and experienced serious hypersensitivity reactions 
(urticaria, rash, and hypersensitivity). All three patients’ events occurred within 72 hours 
of infusion. One patient with type A ASMD experienced two severe 
allergic/anaphylactic-like reactions during infusion that responded well to therapy 
(eIND). 
•  There were no anaphylactic reactions reported in adult patients. 
Severity and nature of risk: 
Infusion associated reactions: 
•  Overall, 30 (50.0%) patients experienced a total of 302 mild events, 17 (28.3%) patients 
experienced a moderate event and 1 (1.7%) patient experienced a severe event of IAR. 
•  Similar percentages of pediatric patients and adult patients had IARs (65.0% 
and 55.0%, respectively). Among the most frequently reported IARs, the EAIR was 
higher in pediatric than adult patients for: urticaria (11.35 versus 4.21 patients 
per 100 PY); pyrexia (14.85 versus 3.37); and vomiting (10.38 versus 2.35). The EAIR 
was higher in adult patients than pediatric patients for headache 
(9.72 versus 6.00 patients per 100 PY) and was similar in adult and pediatric patients 
for nausea (5.61 and 6.02, respectively). 
Systemic hypersensitivity: 
•  In one patient of the 3 pediatric patients who experienced systemic hypersensitivity, the 
events were severe ie, anaphylactic reaction (1 patient 1 event). Specifically, in study 
DFI13803, one serious case of anaphylactic reaction 
 occurred at 
week 12 (16-Jul-2019) during infusion (scheduled dose 0.6 mg/kg). This patient was 
successfully desensitized using a tailored regimen. All three pediatric patients have 
continued treatment and are enrolled in LTS13632. 
Anti-drug antibody mediated hypersensitivity reactions: 
•  Overall, 29 of 60 (48.3%) patients in the clinical studies developed treatment-emergent 
ADA; however, the ADA titers were predominantly ≤400 (median ADA titer was 100), 
 
 
 
Important identified 
Risk 
Immunogenicity: Infusion associated reactions (IARs), systemic 
hypersensitivity including anaphylactic reactions, ADA mediated 
hypersensitivity reactions 
which are considered as low response. Only 5 patients, 3 pediatric and 2 adults, 
developed intermediate titers that ranged from 800 to 3200. Some of the TEAEs 
associated with ADA also resemble to IARs and were generally mild-to-moderate and 
clinically manageable. One pediatric patient, who experienced anaphylaxis (described 
above), developed IgE ADA and had a peak IgG ADA titer of 1600, the highest titer in 
the pediatric olipudase alfa safety set. 
•  Overall, there was a higher percentage of patients with treatment emergent IARs in 
patients who developed treatment emergent ADA versus those who did 
not (75.9% versus 41.9%). The treatment emergent IARs with a higher incidence by PT 
in adult or pediatric patients who developed treatment emergent ADA versus those who 
did not, respectively, were: 
-  Adult patients: Urticaria (31.3% versus 0%), Pruritus (18.8% versus 0%) 
-  Pediatric patients: Urticaria (53.8% versus 0%), Pyrexia (46.2% versus 28.6%), 
Erythema (15.4% versus 0%), Abdominal pain (15.4% versus 0%). 
Seriousness and outcome:  
Three pediatric patients (2 in Study DFI13803 Peds and 1 in Study LTS13632) 
experienced protocol-defined IARs/systemic hypersensitivity that were SAEs. No event 
resulted in permanent treatment discontinuation. No serious IARs were reported in study 
DFI12712. 
All patients were found to be positive for IgG ADA, with 2 of 3 patients having peak ADA 
titers in the intermediate range (800-1600), which modestly decreased over time, 
and 1 patient was low titer (200). In addition, 1 patient was positive for IgE ADA. 
All three patients experiencing a serious IAR/systemic hypersensitivity event recovered; 
resumed olipudase alfa treatment; and are currently enrolled in LTS13632.  
Background incidence/prevalence: 
Immunogenicity is specific to the biologic product and does not occur in untreated patients 
with ASMD. 
Systemic hypersensitivity and IARs: 
•  Patients with previous hypersensitivity/allergy to olipudase alfa and its excipients. 
•  Available clinical data suggest children may have greater predisposition, compared to 
adults. 
Additional risk characterization has not been fully established. 
Anti-drug antibody mediated hypersensitivity reactions: 
The immunologic response to olipudase alfa in adult versus pediatric ASMD patients was 
relatively similar. Adults had a median ADA peak titer of 50 (range 50-3200) compared to 
pediatric patients with a median ADA peak titer of 200 (range 50-1600). 
Labelling statements (See Section V.1) and educational materials (see Section V.2) 
•  To remind the prescribing/treating physician with appropriate patient selection for home 
infusion, the HCPs with monitoring of IARs and hypersensitivity/anaphylaxis during and 
post infusion, importance of dose escalation, management of IARs and 
hypersensitivity/anaphylaxis and missed doses. 
•  To remind patients/caregivers with signs and symptoms of IARs and 
hypersensitivity/anaphylaxis, and to report missed dose to the prescribing/treating 
physician. 
Risk factors and risk 
groups 
Preventability 
Impact on the benefit-risk 
balance of the product 
Although systemic hypersensitivity reactions including anaphylaxis; ADA mediated 
hypersensitivity reactions; and IARs have been seen in the clinical program, the overall 
 
Important identified 
Risk 
Immunogenicity: Infusion associated reactions (IARs), systemic 
hypersensitivity including anaphylactic reactions, ADA mediated 
hypersensitivity reactions 
benefit-risk profile remains favorable. The clinical findings support that olipudase alfa has a 
low immunogenicity risk relative to ADA impact on clinical outcomes. 
Public health impact 
The public health impact has not been evaluated. The intended indication is a very rare 
disease. The public health impact of this risk is expected to be low. 
ADA: Anti-Drug Antibody; ASMD: Acid Sphingomyelinase Deficiency; EAIR: Exposure-Adjusted Incident Rate; eIND: Emergency 
Investigational New Drug; ERT: Enzyme Replacement Therapy; HCP: Healthcare Professional; IAR: Infusion Associated Reaction; 
IgE: Immunoglobulin E; IgG: Immunoglobulin G; IV: Intravenous; PT: Preferred Term; PY: Patient Year; SAE: Serious Adverse Event; 
TEAE: Treatment Emergent Adverse Event. 
Table 25 - Important potential risk: Medication errors in home infusion setting 
Important potential 
risk 
Potential mechanism 
Evidence source(s) and 
strength of evidence 
Medication errors in home infusion setting 
There is potential for human error with respect to preparation and administration of the 
product (eg, dose calculation, reconstitution, etc.) in a home infusion setting. 
Potential medication error is listed as an important potential risk in the RMP of other 
marketed ERTs for which home infusion setting is possible. 
Clinical trial experience: 
No medication errors have been identified by the time of data cutoff (15-Mar-2021). 
Characterization of the 
risk 
The risk associated with administration of the product may result in lack of treatment 
efficacy or overdose. 
Risk factors and risk 
groups 
Preventability  
Impact on the benefit-risk 
balance of the product 
Patients receiving medication in home infusion setting. 
Home infusion supervised by HCPs only (see Section V.1). 
Educational materials for HCPs in home setting including a detailed preparation/infusion 
description (see Section V.2). 
While the possibility of medication errors cannot be excluded, patients receiving home 
infusion have an acceptable safety profile, with appropriate education of HCPs 
administering olipudase alfa in the home setting and for selected patients. The product is 
expected to be safely administered at home like other similar ERTs. The benefit-risk profile 
of olipudase alfa is expected to be favorable in home infusion setting. 
Public health impact 
Public health impact has not been evaluated. The benefit of home infusions on public 
health (reducing hospital burden) is expected to outweigh the risks in the treatment of this 
rare disease population requiring chronic and frequent ERT. 
ERT: Enzyme Replacement Therapy; HCP: Healthcare Professional; RMP: Risk Management Plan. 
Table 26 - Important potential risk: Foetal toxicity 
Important potential 
risk 
Foetal toxicity 
Potential mechanism 
Unknown  
Evidence source(s) and 
strength of evidence 
Non-clinical data  
 
Important potential 
risk 
Characterization of the 
risk 
Risk factors and risk 
groups 
Preventability  
Foetal toxicity 
Potential embryo-foetal toxicity 
Pregnant women and WOCBP 
Pregnant women and WOCBP not using effective contraception should be cautioned.  
Advise to use effective contraception during treatment and for 14 days after the last dose, if 
olipudase alfa is discontinued as defined in the labeling section 4.6 of the SmPC. 
(see Section V.1). 
Educational materials for patients (see Section V.2). 
Impact on the benefit-risk 
balance of the product 
Patients with ASMD are treated throughout their lifespan and therefore may include women 
of childbearing potential. Additional data are needed to characterize the safety profile in this 
population. 
Public health impact 
ASMD: Acid Sphingomyelinase Deficiency; SmPC: Summary of Product Characteristics; WOCBP: Women of Childbearing Potential. 
Public health impact has not been evaluated.  
SVII.3.2  Presentation of the missing information  
Table 27 - Missing information: Use in lactating women  
Missing Information 
Use in lactating women 
Evidence source(s) and 
strength of evidence 
Patients with ASMD are treated throughout their lifespan and therefore may include 
lactating women. Olipudase alfa has been detected in the milk of lactating mice. 
Non-clinical data do not suggest adverse effects on growth and development of nursing 
pups. 
Anticipated 
risk/consequence of the 
missing information 
ASMD: Acid Sphingomyelinase Deficiency; SmPC: Summary of Product Characteristics. 
Potential adverse effects in breastfed babies. 
Caution in exposing this population as defined in the labeling section 4.6 of the SmPC. 
Table 28 - Missing information: Long-term safety (beyond 2 years)  
Missing Information 
Long-term safety (beyond 2 years) 
Evidence source(s) and 
strength of evidence 
Anticipated 
risk/consequence of the 
missing information 
Patients with ASMD are treated throughout their lifespan. 
The benefit-risk profile of olipudase alfa is expected to remain favorable in type A/B and 
type B ASMD patients already exposed to olipudase alfa for more than 2 years. 
Therapeutic proteins have the potential to induce immunogenicity and generate ADA. 
However, not all ADA have clinical consequences. The majority of patients developed a low 
ADA response (ADA titer ≤400). The immunologic response to olipudase alfa in adult 
versus pediatric ASMD patients was relatively similar. In general, ADA titers tended to 
slowly decrease over time, but of note, did not increase with repeated exposure to drug. 
Overall, the median peak ADA titer since the first dose of olipudase alfa was 200 for 
pediatric patients and decreased to 100 by the end of the study. In adult patients, the 
median peak ADA titer was 75 and decreased to 50. In addition, 6.7% of patients tolerized 
or reverted to become ADA-negative by the end of the study. These data support that 
olipudase alfa has a low immunogenicity risk relative to ADA impact on clinical outcomes. 
 
Missing Information 
Long-term safety (beyond 2 years) 
Long-term use safety data beyond 2 years in ASMD patients will be collected through the 
ongoing studies LTS13632 in adults and pediatric patients and DFI12712 ASCEND ETP in 
adult patients. Patients currently enrolled in the clinical studies are expected to continue 
treatment with commercial product and will be monitored through routine 
pharmacovigilance. 
ADA: Anti-Drug Antibody; ASMD: Acid Sphingomyelinase Deficiency; ETP: Extension Treatment Period. 
 
RISK MANAGEMENT PLAN - PART II MODULE SVIII: SUMMARY OF THE 
SAFETY CONCERNS  
Important identified risk 
Immunogenicity: 
Summary of the safety concerns 
•  Infusion associated reactions (IARs), 
•  Systemic hypersensitivity including anaphylactic reactions, 
•  Anti-Drug Antibody (ADA) mediated hypersensitivity reactions. 
Important potential risks 
Missing information 
Medication errors in home infusion setting 
Foetal toxicity 
Use in lactating women 
Long-term safety (beyond 2 years) 
ADA: Anti-Drug Antibody; IAR: Infusion Associated Reaction. 
 
 
RISK MANAGEMENT PLAN - PART III: PHARMACOVIGILANCE PLAN 
(INCLUDING POST-AUTHORIZATION SAFETY STUDIES)  
III.1 
ROUTINE PHARMACOVIGILANCE ACTIVITIES  
The safety profile of olipudase alfa will be continuously monitored from product launch, using 
following routine pharmacovigilance activities: 
•  Routine pharmacovigilance practices allowing a comprehensive, continuous and global 
overview of postmarketing safety profile of olipudase alfa and signal detection. 
•  Periodic assessment in periodic safety update reports (PSURs)/periodic benefit-risk 
evaluation report (PBRER) for spontaneous reports related to identified and potential risks. 
•  Continued analysis of safety in clinical trials. 
The ongoing clinical trial program (DFI12712 and LTS13632) includes safety assessment with 
collection of adverse events of special interest (AESIs) which are defined as AEs, serious or 
nonserious, that need to be monitored, documented and managed in a pre-specified manner. These 
AESIs include pregnancy, symptomatic overdose, laboratory values meeting pre-specified criteria 
(dose limiting toxicities based on transaminase and alkaline phosphatase levels and symptoms), 
Infusion-associated reactions including hypersensitivity reactions, APRs and cytokine release 
syndrome). 
In addition to the Sponsor, an external independent data monitoring committee (DMC) was, and 
will continue to be responsible for monitoring the safety of patients enrolled in phase 2/3 trials 
(DFI12712 ASCEND and LTS13632) up to the approval for marketing authorization of olipudase 
alfa of the three major markets (EU, US or Japan). 
III.2 
ADDITIONAL PHARMACOVIGILANCE ACTIVITIES  
Additional pharmacovigilance in the postmarketing setting includes: 
•  An ongoing multinational, multicenter, nonrandomized, open-label, long-term extension, 
maintenance trial LTS13632 (final report planned in 2024) which aims to assess the 
long-term safety (up to 9 years) of olipudase alfa in adult and pediatric patients with ASMD 
(see details below and protocol in [Part VII Annex 3]). 
•  An ongoing extension phase of phase 2/3 clinical trial (DFI12712 ASCEND), multicenter, 
randomized, double-blind, placebo-controlled, repeat-dose study to evaluate the efficacy, 
safety, PD and PK of olipudase alfa in adult patients with ASMD (see details below and 
protocol in [Part VII Annex 3]). 
 
Table 29 - Additional pharmacovigilance activities (category 1 to 3) summary  
LTS13632 - A long-term clinical trial - ongoing (Cat. 3) 
Study short name and title 
LTS13632 - A long-term study to assess the ongoing safety and efficacy of olipudase alfa in patients with ASMD 
Rationale and study objectives 
To obtain data regarding the safety and efficacy of olipudase alfa in patients with ASMD who are exposed to long-term 
treatment with olipudase alfa. 
Primary objective: 
To assess the long-term safety of olipudase alfa in patients with ASMD. 
Secondary objective: 
To assess the maintenance of effect of olipudase alfa and to characterize the PDs and PKs following long-term 
administration. 
Study design 
Multinational, multicenter, non-randomized, open-label, long-term treatment study of patients who completed the treatment 
period of the DFI13412 or DFI13803 Peds, respectively, with an acceptable safety profile. 
Patients are receiving olipudase alfa every 2 weeks for 9 years or marketing approval, whichever comes first. Patients 
started this study at the same dose they were receiving at the end of their primary study, provided that they have not 
missed more than 1 biweekly dose between studies. 
Study populations 
Pediatric and adult patients with ASMD: 25 (5 adults, 20 pediatrics)  
The patient completed the treatment period of a previous study (DFI13412 or DFI13803 Peds) of olipudase alfa with an 
acceptable benefit-risk outcome (in the opinion of the investigator and sponsor). 
The patient has no new condition or worsening of an existing condition which in the opinion of the investigator would 
preclude the patient from enrollment in the open label extension phase or could interfere with the patient participating in or 
completing the study. 
Milestones 
First patient First Visit: 04-Dec-2013 
First Interim Report: Cut-off date 10-Dec-2019 
Second Interim Report: Cut-off date 01-Mar-2021 included in the initial MAA 
Last patient Last Visit: 06-Sep-2023 
Final Study Report submission planned: Aug-2024 
DFI12712 ASCEND Adults Phase 2/3 clinical trial - ongoing (Cat. 3) 
Study short name and title 
DFI12712 - A phase 2/3, multicenter, randomized, double-blinded, placebo-controlled, repeat-dose study to evaluate the 
efficacy, safety, PDs, and PKs of olipudase alfa in patients with ASMD 
Rationale and study objectives 
To evaluate the efficacy, safety, PDs and PKs of olipudase alfa in adult patients with ASMD. 
Primary objective:  
To evaluate the efficacy of olipudase alfa (recombinant human acid sphingomyelinase) administered intravenously once 
every 2 weeks for 52 weeks in adult patients with ASMD by assessing changes in. 
•  Spleen volume as measured by abdominal MRI. 
•  Infiltrative lung disease as measured by the pulmonary function test, diffusing capacity of the lung for carbon monoxide. 
 
Secondary objectives:  
•  To confirm the safety of olipudase alfa administered intravenously once every 2 weeks for 52 weeks. 
•  To characterize the effect of olipudase alfa on the patient perception related to spleen volume as measured by SRS 
after 52 weeks of study drug administration. 
•  To characterize the effect of olipudase alfa on the following endpoints assessed sequentially: 
-  The effect of olipudase alfa on liver volume after 52 weeks of study drug administration 
-  The effect of olipudase alfa on platelet count after 52 weeks of study drug administration 
-  The effect of olipudase alfa after 52 weeks of study drug administration on fatigue 
-  The effect of olipudase alfa after 52 weeks of study drug administration on pain 
-  The effect of olipudase alfa after 52 weeks of study drug administration on dyspnea 
Study design 
A Phase 2/3 clinical trial, multicenter, randomized, double-blinded, placebo-controlled, repeat-dose study. 
The trial was divided into 2 consecutive major periods:  
•  A randomized placebo-controlled double-blind PAP from day 60 to week 52 followed by  
•  An ETP that resulted in a total study period of up to 5 years and 3 months in duration. 
Study populations 
Adults, 18 years or older, with a documented deficiency of ASM, as measured by ASM activity in peripheral leukocytes, 
cultured fibroblasts, or lymphocytes; and a clinical diagnosis consistent with ASMD. 
Primary Analysis Period: 36 (18 placebo, 18 olipudase alfa) 
Extension Treatment Period: 36 (18 placebo/olipudase alfa, 18 olipudase alfa/olipudase alfa) 
Milestones 
First patient first visit: 17-Dec-2015  
Last patient last visit for PAP: 17-Oct-2019  
First Interim Report: Cut-off date 17-Oct-2019 
Second Interim Report: Cut-off date 15-Mar-2021 included in the initial MAA 
Last patient last visit for ETP: anticipated Oct-2023  
Final Study Report submission planned: Aug-2024 
ASM: Acid Sphingomyelinase; ASMD: Acid Sphingomyelinase Deficiency; ETP: Extension Treatment Period; MAA: Marketing 
Authorization Application; MRI: Magnetic Resonance Imaging; PAP: Primary Analysis Period; PD: Pharmacodynamic; 
PK: Pharmacokinetic; SRS: Splenomegaly Related Score. 
III.3 
SUMMARY TABLE OF ADDITIONAL PHARMACOVIGILANCE ACTIVITIES  
Table 30 - Ongoing and planned additional pharmacovigilance activities  
Study status 
Summary of objectives  Safety concerns 
Milestones  Due dates 
addressed 
Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing 
authorization 
Not applicable 
Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a 
conditional marketing authorization or a marketing authorization under exceptional circumstances  
Not applicable 
 
Study status 
Summary of objectives  Safety concerns 
Milestones  Due dates 
Category 3 - Required additional pharmacovigilance activities 
addressed 
•  Immunogenicity: Infusion 
Associated Reactions 
(IARs), systemic 
hypersensitivity including 
anaphylactic reactions, 
Anti-Drug Antibody (ADA) 
mediated hypersensitivity 
reactions. 
•  Medication errors in home 
infusion setting. 
•  Long-term safety 
(beyond 2 years). 
•  Immunogenicity: Infusion 
Associated Reactions 
(IARs), systemic 
hypersensitivity including 
anaphylactic reactions, 
Anti-Drug Antibody (ADA) 
mediated hypersensitivity 
reactions. 
•  Medication errors in home 
infusion setting. 
•  Long-term safety 
(beyond 2 years). 
04-Dec-2013 
Cut-off date 
10-Dec-2019  
Cut-off date 
01-Mar-2021 
included in the 
initial MAA 
06-Sep-2023 
Aug-2024 
17-Dec-2015 
17-Oct-2019 
Cut-off date 
17-Oct-2019 
Cut-off date 
15-Mar-2021 
included in the 
initial MAA 
Anticipated 
Oct-2023  
Aug-2024 
First patient 
First Visit: 
First Interim 
Report: 
Second Interim 
Report:  
Last patient 
Last Visit: 
Final study 
Report 
submission 
planned: 
First patient 
First visit: 
Last patient 
Last Visit for 
PAP: 
First Interim 
Report: 
Second Interim 
Report:  
Last patient last 
visit for ETP: 
Final study 
Report 
submission 
planned: 
LTS13632 - A 
long-term study to 
assess the ongoing 
safety and efficacy 
of olipudase alfa in 
patients with 
ASMD 
Ongoing 
DFI12712 
ASCEND  
A Phase 2/3, 
multicenter, 
randomized, 
double-blinded, 
placebo-controlled, 
repeat-dose study 
to evaluate the 
efficacy, safety, 
PDs, and PKs of 
olipudase alfa in 
patients with 
ASMD 
Ongoing 
To obtain data regarding the 
safety and efficacy of 
olipudase alfa in patients with 
ASMD who are exposed to 
long-term treatment with 
olipudase alfa. 
Primary objective: 
To assess the long-term safety 
of olipudase alfa in patients 
with ASMD. 
Secondary objective: 
To assess the maintenance of 
effect of olipudase alfa and to 
characterize the PDs and PKs 
following long-term 
administration. 
To evaluate the efficacy, 
safety, PDs and PKs of 
olipudase alfa in adult patients 
with ASMD. 
Primary objectives:  
To evaluate the efficacy of 
olipudase alfa (recombinant 
human acid 
sphingomyelinase) 
administered intravenously 
once every 2 weeks 
for 52 weeks in adult patients 
with ASMD by assessing 
changes in: 
•  Spleen volume as 
measured by abdominal 
MRI. 
•  Infiltrative lung disease as 
measured by the pulmonary 
function test, diffusing 
capacity of the lung for 
carbon monoxide. 
Secondary objectives:  
•  To confirm the safety of 
olipudase alfa administered 
intravenously once 
every 2 weeks 
for 52 weeks. 
•  To characterize the effect of 
olipudase alfa on the 
 
 
 
 
 
 
 
 
 
 
Study status 
Summary of objectives  Safety concerns 
Milestones  Due dates 
addressed 
patient perception related to 
spleen volume as 
measured by SRS 
after 52 weeks of study 
drug administration. 
•  To characterize the effect of 
olipudase alfa on the 
following endpoints 
assessed sequentially: 
-  The effect of olipudase 
alfa on liver volume 
after 52 weeks of study 
drug administration 
-  The effect of olipudase 
alfa on platelet count 
after 52 weeks of study 
drug administration 
-  The effect of olipudase 
alfa after 52 weeks of 
study drug administration 
on fatigue 
-  The effect of olipudase 
alfa after 52 weeks of 
study drug administration 
on pain 
-  The effect of olipudase 
alfa after 52 weeks of 
study drug administration 
on dyspnea 
ADA: Anti-Drug Antibody; ASMD: Acid Sphingomyelinase Deficiency; ETP: Extension Treatment Period; IAR: Infusion Associated 
Reaction; MAA: Marketing Authorization Application; MRI: Magnetic Resonance Imaging; PAP: Primary Analysis Period; 
PD: Pharmacodynamic; PK: Pharmacokinetic; SRS: Splenomegaly Related Score. 
 
RISK MANAGEMENT PLAN PART IV: PLANS FOR 
POST-AUTHORIZATION EFFICACY STUDIES  
No imposed post-authorization efficacy studies as a condition of the marketing authorization or 
which are specific obligations in the context of conditional marketing authorization or marketing 
authorization under exceptional circumstances are planned or ongoing for olipudase alfa. 
 
 
RISK MANAGEMENT PLAN - PART V: RISK MINIMIZATION MEASURES 
(INCLUDING EVALUATION OF THE EFFECTIVENESS OF RISK 
MINIMIZATION ACTIVITIES)  
The risk management strategy for olipudase alfa consists in routine risk minimization measures 
(such as communication on the risks, specific clinical measures and legal status reported in the 
product information aimed to patients and HCPs) (see Table 31) and additional risk minimization 
measures (ie, educational materials) (see Table 32). 
V.1  ROUTINE RISK MINIMIZATION MEASURES  
Table 31 - Description of routine risk minimization measures by safety concern  
Safety concern 
Routine risk minimization activities 
Immunogenicity:  
Routine risk communication: 
•  Infusion Associated 
Reactions (IARs), 
•  Systemic hypersensitivity 
including anaphylactic 
reactions, 
•  Anti-drug antibody (ADA) 
mediated hypersensitivity 
reactions 
Medication errors in home 
infusion setting  
•  Labeled in sections 4.4 and 4.8 of the SmPC. 
•  Labeled in section 4 of the PL. 
Routine risk minimization activities recommending specific clinical measures 
to address the risk: 
•  Labeled in sections 4.2, 4.3 and 4.4 of the SmPC. 
•  Labeled in sections 2, 3 and 4 of the PL. 
Other routine risk minimization measures beyond the Product Information: 
Legal status: 
Restricted medical prescription. 
Routine risk communication: 
None 
Routine risk minimization activities recommending specific clinical measures 
to address the risk: 
None 
Other routine risk minimization measures beyond the Product Information: 
Legal status: 
Restricted medical prescription. 
Foetal toxicity 
Routine risk communication: 
•  Labeled in sections 4.6 and 5.3 of the SmPC. 
•  Labeled in section 2 of the PL. 
Routine risk minimization activities recommending specific clinical measures 
to address the risk: 
•  Labeled in section 4.6 of the SmPC. 
•  Labeled in section 2 of the PL. 
Other routine risk minimization measures beyond the Product Information: 
Legal status: 
Restricted medical prescription. 
 
Safety concern 
Routine risk minimization activities 
Use in lactating women 
Routine risk communication: 
Long-term safety 
(beyond 2 years) 
•  Labeled in sections 4.6 and 5.3 of the SmPC. 
•  Labeled in section 2 of the PL. 
Routine risk minimization activities recommending specific clinical measures 
to address the risk: 
•  Labeled in section 4.6 of the SmPC. 
•  Labeled in section 2 of the PL. 
Other routine risk minimization measures beyond the Product Information: 
Legal status:  
Restricted medical prescription. 
Routine risk communication: 
Labeled in section 4.8 of the SmPC. 
Routine risk minimization activities recommending specific clinical measures 
to address the risk: 
None 
Other routine risk minimization measures beyond the Product Information: 
Legal status: 
Restricted medical prescription. 
ADA: Anti-Drug Antibody; IAR: Infusion Associated Reaction; PL: Package Leaflet; SmPC: Summary of Product Characteristics. 
V.2  ADDITIONAL RISK MINIMIZATION MEASURES  
Table 32 - Additional risk minimization measures  
A HCP guide for HCPs in home infusion setting including nurses 
Objectives 
Rationale for the additional risk 
minimization activity 
This guide is designed to support home infusion HCPs and nurses in managing the 
following risks associated with the home use of olipudase alfa:  
•  Immunogenicity: Infusion-associated reactions (IARs), systemic hypersensitivity 
including anaphylactic reactions, ADA mediated hypersensitivity reactions. 
•  Medication errors in home infusion setting. 
The guide is considered necessary and complementary to the product information, to 
re-inforce the key safety messages/instructions associated with olipudase alfa use. 
In addition, the guide includes contact information of the prescribing/ treating 
physician/centre that can be reached at any time, information on signs and 
symptoms related to IARs, hypersensitivity/anaphylaxis and recommended actions 
for the management of ADRs when symptoms occur, medical evaluation of the 
patients prior to administration of the infusion at home, requirements and 
organization of the home infusion, details and instructions on the preparation, 
reconstitution, dilution and administration, a calculation template as a basis for 
recording infusion details in the patient’s medical record.  
Target audience and planned 
distribution path 
Target audiences: 
Healthcare professionals and nurses responsible for the preparation and/or 
administration of olipudase alfa in home setting. 
 
Plans to evaluate the 
effectiveness of the 
interventions and criteria for 
success 
Distribution paths: 
To be adapted country by country depending on each local situation and public 
health system: mail, face to face distribution, electronic (email, web link, 
QR Code/URL). 
Periodicity of the distribution: 
One single distribution at launch, then redistribution (eg, once a year, ad-hoc) can 
occur according to local regulatory requirements or national health systems. 
Plans to evaluate the effectiveness of the interventions: 
Distribution Process outcome. 
Spontaneous reports of IARs, systemic hypersensitivity including anaphylactic 
reactions, and ADA mediated hypersensitivity reactions in home infusion setting. 
Spontaneous reports of medication errors. 
Criteria for judging success:  
Implementation status of the distribution plan, at each participating country level. 
Routine pharmacovigilance.  
A Patient Card for patients/caregivers 
Objectives 
Rationale for the additional risk 
minimization activity 
Target audience and planned 
distribution path 
This card is aimed to mitigate the risk of IARs of systemic hypersensitivity and their 
negative clinical consequences and provide instruction to WOCBP including in case 
of pregnancy. 
The patient card is considered necessary and complementary to the PL.  
•  To remind through a synthetic tool the signs and symptoms of IARs, so that 
patients/caregivers can react quickly, allowing early intervention and medical care. 
•  To remind the WOCBP to discuss with the prescribing/treating physician the need 
for effective contraceptive measures during treatment and for 14 days after the 
last dose if XENPOZYME is discontinued. 
•  To remind the WOCBP to contact their prescribing/treating physician if they 
suspect they might be pregnant or plan pregnancy. 
•  To document the prescribing/treating physician’s emergency contact information 
for easy agreed reference. 
•  To provide patients with electronic access to patient card and PL in countries 
where applicable.  
•  The wallet size format enables the information to be easily available and shown to 
any HCP easily. 
Target audiences:  
Acid Sphingomyelinase Deficiency patients and/or caregivers through the 
prescribing/treating physicians and/or HCPs administering the treatment. 
Distribution paths: 
Educational materials for patients will be distributed as hard copies (and in digital 
format where possible via QR Code/URL) via prescribing/treating physicians or 
HCPs administering the treatment, depending on the local country options and 
requirements. 
Periodicity of the distribution: 
One single distribution at launch, then redistribution (eg, once a year, ad-hoc.) could 
be envisaged according to local regulatory requirements and national healthcare 
systems. 
 
Plans to evaluate the 
effectiveness of the 
interventions and criteria for 
success 
Plans to evaluate the effectiveness of the interventions: 
Distribution Process outcome. 
Criteria for judging success: 
Implementation of the distribution plan, within each country. 
Routine pharmacovigilance.  
ADA: Anti-Drug Antibody; ADR: Adverse Drug Reaction; HCP: Healthcare Professional; IAR: Infusion Associated Reaction; PL: Package 
Leaflet; QR: Quick Response; URL: Uniform Resource Locator; WOCBP: Women of Childbearing Potential. 
V.3  SUMMARY OF RISK MINIMIZATION MEASURES  
Table 33 - Summary table of pharmacovigilance activities and risk minimization activities by safety 
concern  
Safety concern 
Risk minimization measures 
Pharmacovigilance activities 
Immunogenicity: 
Routine risk minimization measures: 
•  Sections 4.2, 4.3, 4.4 and 4.8 of the 
SmPC. 
•  Sections 2, 3 and 4 of the PL. 
•  Legal Status: Restricted medical 
prescription. 
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: 
None 
Additional pharmacovigilance 
activities: 
Additional risk minimization measures: 
•  A HCP Guide for HCPs in home infusion 
•  Study LTS13632  
•  Study DFI12712 (ASCEND) 
•  Infusion Associated 
Reactions (IAR), 
•  Systemic hypersensitivity 
including anaphylactic 
reactions, 
•  Anti-drug antibody (ADA) 
mediated hypersensitivity 
reactions 
Medication errors in home 
infusion setting  
setting including nurses. 
•  A Patient Card for patients/caregivers. 
Routine risk minimization measures: 
Legal Status: Restricted medical 
prescription.  
Additional risk minimization measures: 
A HCP Guide for HCPs in home infusion 
setting including nurses. 
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: 
None 
Additional pharmacovigilance 
activities: 
•  Study LTS13632  
•  Study DFI12712 (ASCEND) 
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: 
None 
Additional pharmacovigilance 
activities: 
None  
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: 
None 
Additional pharmacovigilance 
activities: 
None  
Foetal toxicity 
Routine risk minimization measures: 
•  Sections 4.6 and 5.3 of the SmPC. 
•  Section 2 of the PL. 
•  Legal status: Restricted medical 
prescription.  
Additional risk minimization measures: 
A Patient Card for patients/caregivers. 
Use in lactating women 
Routine risk minimization measures: 
•  Sections 4.6 and 5.3 of the SmPC. 
•  Section 2 of the PL. 
•  Legal status: Restricted medical 
prescription.  
Additional risk minimization measures: 
None 
 
Safety concern 
Risk minimization measures 
Pharmacovigilance activities 
Long-term safety (beyond 
2 years) 
Routine risk minimization measures: 
•  Section 4.8 of the SmPC. 
•  Legal status: Restricted medical 
prescription.  
Additional risk minimization measures: 
None 
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: 
None 
Additional pharmacovigilance 
activities: 
•  Study LTS13632  
•  Study DFI12712 (ASCEND)  
ADA: Anti-Drug Antibody; HCP: Healthcare Professional; IAR: Infusion Associated Reaction; PL: Package Leaflet; SmPC: Summary of 
Product Characteristics. 
 
RISK MANAGEMENT PLAN - PART VI: SUMMARY OF THE RISK 
MANAGEMENT PLAN  
Summary of risk management plan for XENPOZYME (Olipudase alfa) 
This is a summary of the risk management plan (RMP) for XENPOZYME. The RMP details 
important risks of XENPOZYME how these risks can be minimized, and how more information 
will be obtained about XENPOZYME’s risks and uncertainties (missing information). 
XENPOZYME’s summary of product characteristics (SmPC) and its package leaflet (PL) give 
essential information to healthcare professionals (HCPs) and patients on how XENPOZYME 
should be used. 
This summary of the RMP for XENPOZYME should be read in the context of all this information 
including the assessment report of the evaluation and its plain-language summary, all which is part 
of the European public assessment report (EPAR). 
Important new concerns or changes to the current ones will be included in updates of 
XENPOZYME’s RMP. 
I. 
THE MEDICINE AND WHAT IT IS USED FOR  
XENPOZYME is an enzyme replacement therapy for the treatment of non-central nervous 
system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) in pediatric and adult 
patients with type A/B or type B. It contains olipudase alfa as the active substance, a recombinant 
human acid sphingomyelinase produced in a Chinese hamster ovary (CHO) cell line by 
recombinant deoxyribonucleic acid (DNA) technology. XENPOZYME is given by intravenous (IV) 
infusion. 
Further information about the evaluation of XENPOZYME’s benefits can be found in 
XENPOZYME’s EPAR, including in its plain-language summary, available on the European 
medicines agency (EMA) website, under the medicine’s webpage: 
https://www.ema.europa.eu/en/medicines/human/EPAR/xenpozyme  
II. 
RISKS ASSOCIATED WITH THE MEDICINE AND ACTIVITIES TO MINIMIZE OR 
FURTHER CHARACTERIZE THE RISKS  
Important risks of XENPOZYME, together with measures to minimize such risks and the studies 
for learning more about XENPOZYME’s risks are outlined in the next sections.  
Measures to minimize the risks identified for medicinal products can be: 
•  Specific information, such as warnings, precautions, and advise on correct use, in the PL 
and SmPC addressed to patients and HCPs respectively; 
 
• 
Important advise on the medicine’s packaging; 
•  The authorized pack size - the amount of medicine in a pack is chosen so to ensure that the 
medicine is used correctly; 
•  The medicine’s legal status - the way a medicine is supplied to the patient (eg, with or 
without prescription) can help to minimize its risks. 
Together, these measures constitute routine risk minimization measures. 
In the case of XENPOZYME, these measures are supplemented with additional risk minimization 
measures mentioned under relevant important risks, outlined in the next sections. 
In addition to these measures, information about adverse reactions will be collected continuously 
and regularly analyzed, including periodic safety update report (PSUR) assessment so that 
immediate action can be taken as necessary. These measures constitute routine pharmacovigilance 
activities. 
If important information that may affect the safe use of XENPOZYME is not yet available, it is 
listed under “missing information” outlined in the next section. 
II.A 
List of important risks and missing information  
Important risks of XENPOZYME are risks that need special risk management activities to further 
investigate or minimize the risk, so that the medicinal product can be safely administered. Important 
risks can be regarded as identified or potential. Identified risks are concerns for which there is 
sufficient proof of a link with the use of XENPOZYME. Potential risks are concerns for which an 
association with the use of this medicine is possible based on available data, but this association has 
not been established yet and needs further evaluation. Missing information refers to information on 
the safety of the medicinal product that is currently missing and needs to be collected (eg, on the 
long-term use of the medicine). 
Table 34 - List of important risks and missing information  
Important identified risk 
Immunogenicity: 
•  Infusion associated reactions (IARs), 
•  Systemic hypersensitivity including anaphylactic reactions, 
•  Anti-drug antibody (ADA) mediated hypersensitivity reactions 
Important potential risks 
Missing information 
Medication errors in home infusion setting 
Foetal toxicity 
Use in lactating women 
Long-term safety (beyond 2 years) 
ADA: Anti-Drug Antibody; IAR: Infusion Associated Reaction. 
 
II.B 
Summary of important risks  
Table 35 - Important identified risk with corresponding risk minimization activities and additional 
pharmacovigilance activities: Immunogenicity: Infusion associated reactions (IAR), systemic 
hypersensitivity including anaphylactic reactions, Anti-Drug Antibody (ADA) mediated 
hypersensitivity reactions  
Immunogenicity: Infusion associated reactions (IAR), systemic hypersensitivity including 
anaphylactic reactions, Anti-Drug Antibody (ADA) mediated hypersensitivity reactions 
Evidence for linking the risk to 
the medicine 
Risk factors and risk groups 
Clinical trial experience, class effects, scientific literature, other (eIND). 
Systemic hypersensitivity and IARs: 
•  Patients with previous hypersensitivity/allergy to olipudase alfa and its excipients. 
•  Available clinical data suggest children may have greater predisposition, compared 
to adults. 
Additional risk characterization has not been fully established. 
Anti-drug antibody mediated hypersensitivity reactions: 
The immunologic response to olipudase alfa in adult versus pediatric ASMD patients 
was relatively similar. Adults had a median ADA peak titer of 50 (range 50-3200) 
compared to pediatric patients with a median ADA peak titer of 200 (range 50-1600). 
Risk minimization measures 
Routine risk minimization measures: 
Additional pharmacovigilance 
activities 
•  Sections 4.2, 4.3, 4.4 and 4.8 of the SmPC. 
•  Sections 2, 3 and 4 of the PL. 
•  Legal Status: Restricted medical prescription. 
Additional risk minimization measures: 
•  A HCP Guide for HCPs in home infusion setting including nurses. 
•  A Patient Card for patients/caregivers. 
Additional pharmacovigilance activities: 
•  Study LTS13632 
•  Study DFI12712 (ASCEND) 
See Section II.C of this summary for an overview of the post-authorization 
development plan. 
ADA: Anti-Drug Antibody; ASMD: Acid Sphingomyelinase Deficiency; eIND: Emergency Investigational New Drug; HCP: Healthcare 
Professional; IAR: Infusion Associated Reaction; PL: Package Leaflet; SmPC: Summary of Product Characteristics. 
Table 36 - Important potential risk with corresponding risk minimization activities and additional 
pharmacovigilance activities: Medication errors in home infusion setting  
Medication errors in home infusion setting 
Evidence for linking the risk to 
the medicine 
Potential medication error is listed as an important potential risk in the RMP of other 
marketed ERTs for which home infusion setting is possible.  
Clinical trial experience:  
No medication errors have been identified by the time of data cutoff (15-Mar-2021). 
Risk factors and risk groups 
Patients receiving medication in home infusion setting. 
 
Medication errors in home infusion setting 
Risk minimization measures 
Additional pharmacovigilance 
activities 
Routine risk minimization measures: 
Legal Status: Restricted medical prescription.  
Additional risk minimization measures: 
A HCP guide for HCPs in home infusion setting including nurses. 
Additional pharmacovigilance activities: 
•  Study LTS13632 
•  Study DFI12712 (ASCEND) 
See Section II.C of this summary for an overview of the post-authorization 
development plan. 
ERT: Enzyme Replacement Therapy; HCP: Healthcare Professional; RMP: Risk Management Plan. 
Table 37 - Important potential risk with corresponding risk minimization activities: Foetal toxicity  
Foetal toxicity 
Evidence for linking the risk to 
the medicine 
Non-clinical data 
Risk factors and risk groups 
Pregnant women and WOCBP. 
Risk minimization measures 
Routine risk minimization measures: 
•  Sections 4.6 and 5.3 of the SmPC. 
•  Section 2 of the PL. 
•  Legal status: Restricted medical prescription.  
Additional risk minimization measures: 
A Patient Card for patients/caregivers. 
PL: Package Leaflet; SmPC: Summary of Product Characteristics; WOCBP: Women of Childbearing Potential.  
Table 38 - Missing information with corresponding risk minimization activities: Use in lactating 
women  
Use in lactating women 
Risk minimization measures 
Routine risk minimization measures: 
•  Sections 4.6 and 5.3 of the SmPC. 
•  Section 2 of the PL. 
•  Legal status: Restricted medical prescription.  
Additional risk minimization measures: 
None 
PL: Package Leaflet; SmPC: Summary of Product Characteristics. 
 
Table 39 - Missing information with corresponding risk minimization activities and additional 
pharmacovigilance activities: Long-term safety (beyond 2 years)  
Long-term safety (beyond 2 years)  
Risk minimization measures 
Routine risk minimization measures: 
•  Section 4.8 of the SmPC. 
•  Legal status: Restricted medical prescription.  
Additional risk minimization measures: 
None 
Additional pharmacovigilance activities: 
•  Study LTS13632  
•  Study DFI12712 (ASCEND) 
Additional pharmacovigilance 
activities 
SmPC: Summary of Product Characteristics. 
II.C 
Post-authorization development plan  
II.C.1 
Studies which are conditions of the marketing authorization  
There are no studies which are conditions of the marketing authorization or specific obligation of 
XENPOZYME. 
II.C.2 
Other studies in post-authorization development plan  
Table 40 - Other studies in post-authorization development plan  
LTS13632 - A long-term clinical trial (Cat. 3) 
Purpose of the study: 
To obtain data regarding the safety and efficacy of olipudase alfa in patients with ASMD who are exposed to long-term 
treatment with olipudase alfa. 
Primary objective: 
To assess the long-term safety of olipudase alfa in patients with ASMD. 
Secondary objective: 
To assess the maintenance of effect of olipudase alfa and to characterize the PDs and PKs following long-term 
administration. 
DFI12712 ASCEND Adults Phase 2/3 clinical trial (Cat. 3) 
Purpose of the study: 
To evaluate the efficacy, safety, PDs and PKs of olipudase alfa in adult patients with ASMD. 
Primary objectives:  
To evaluate the efficacy of olipudase alfa (recombinant human acid sphingomyelinase) administered intravenously once 
every 2 weeks for 52 weeks in adult patients with ASMD by assessing changes in: 
•  Spleen volume as measured by abdominal MRI. 
•  Infiltrative lung disease as measured by the pulmonary function test, diffusing capacity of the lung for carbon monoxide. 
Secondary objectives:  
•  To confirm the safety of olipudase alfa administered intravenously once every 2 weeks for 52 weeks. 
•  To characterize the effect of olipudase alfa on the patient perception related to spleen volume as measured by SRS 
after 52 weeks of study drug administration. 
 
•  To characterize the effect of olipudase alfa on the following endpoints assessed sequentially: 
-  The effect of olipudase alfa on liver volume after 52 weeks of study drug administration 
-  The effect of olipudase alfa on platelet count after 52 weeks of study drug administration 
-  The effect of olipudase alfa after 52 weeks of study drugs administration on fatigue 
-  The effect of olipudase alfa after 52 weeks of study drug administration on pain 
-  The effect of olipudase alfa after 52 weeks of study drug administration on dyspnea 
ASMD: Acid Sphingomyelinase Deficiency; MRI: Magnetic Resonance Imaging; PD: Pharmacodynamic; PK: Pharmacokinetic; 
SRS: Splenomegaly Related Score. 
 
 
REFERENCES  
Wang RY, Bodamer OA, Watson MS, Wilcox WR. Lysosomal storage diseases: diagnostic 
1. 
confirmation and management of presymptomatic individuals. Genet Med. 2011 May;13(5):457-84. 
McGovern MM, Wasserstein MP, Bembi B, Giugliani R, Mengel KE, Vanier MT, et al. 
2. 
Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and 
adults: eleven years of observation. Orphanet J Rare Dis. 2021 May 10;16(1):1-14. 
Cox GF, Clarke LA, Giugliani R, McGovern MM. Burden of Illness in Acid 
3. 
Sphingomyelinase Deficiency: A Retrospective Chart Review of 100 Patients. JIMD Rep. 
2018;41:119-29. 
4. 
Kingma SD, Bodamer OA, Wijburg FA. Epidemiology and diagnosis of lysosomal storage 
disorders; challenges of screening. Best Pract Res Clin Endocrinol Metab. 2015 Mar;29(2):145-57. 
Schuchman EH, Wasserstein MP. Types A and B Niemann-Pick disease. Best Pract Res 
5. 
Clin Endocrinol Metab. 2015 Mar;29(2):237-47. 
6. 
McGovern MM, Avetisyan R, Sanson BJ, Lidove O. Disease manifestations and burden of 
illness in patients with acid sphingomyelinase deficiency (ASMD). Orphanet J Rare Dis. 2017 Feb 
23;12(1):41. 
Simonaro CM, Desnick RJ, McGovern MM, Wasserstein MP, Schuchman EH. The 
7. 
demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new 
genotype/phenotype correlations. Am J Hum Genet. 2002 Dec;71(6):1413-9. 
Prevalence of rare diseases: Bibliographic data [Internet]. Orphanet Report Series, Rare 
8. 
Diseases collection, Number 1: Diseases in alphabetical order. 2016. [Cited 2020 Sep 11]. 
Available from: 
http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list
.pdf 
Schuchman EH, Miranda SR. Niemann-Pick disease: mutation update, genotype/phenotype 
9. 
correlations, and prospects for genetic testing. Genet Test. 1997;1(1):13-9. 
10.  Acuna M, Martinez P, Moraga C, He X, Moraga M, Hunter B, et al. Epidemiological, 
clinical and biochemical characterization of the p.(Ala359Asp) SMPD1 variant causing Niemann-
Pick disease type B. Eur J Hum Genet. 2016 Feb;24(2):208-13. 
11.  McGovern MM, Lippa N, Bagiella E, Schuchman EH, Desnick RJ, Wasserstein MP. 
Morbidity and mortality in type B Niemann–Pick disease. Genet Med. 2013 Aug;15(8):618-23. 
12.  Wasserstein M, Dionisi-Vici C, Giugliani R, Hwu WL, Lidove O, Lukacs Z, et al. 
Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency 
(ASMD). Mol Genet Metab. 2019 Feb;126(2):98-105. 
13.  Mannem H, Kilbourne S, Weder M. Lung transplantation in a patient with Niemann-Pick 
disease. J Heart Lung Transplant. 2019 Jan;38(1):100-1. 
 
14.  O'Neill RS, Belousova N, Malouf MA. Pulmonary Type B Niemann-Pick Disease 
Successfully Treated with Lung Transplantation. Case Rep Transplant. 2019 Jun 16;2019:9431751. 
15.  Ding F, Mehta AC, Arrossi AV. Successful lung transplantation in a patient with Niemann‒
Pick disease. J Heart Lung Transplant. 2019 May;38(5):582-3. 
Scaggiante B, Pineschi A, Sustersich M, Andolina M, Agosti E, Romeo D. Successful 
16. 
therapy of Niemann-Pick disease by implantation of human amniotic membrane. Transplantation. 
1987 Jul;44(1):59-61. 
17.  Mercati O, Pichard S, Ouachee M, Froissart R, Fenneteau O, Roche B, et al. Limited 
benefits of presymptomatic cord blood transplantation in neurovisceral acid sphingomyelinase 
deficiency (ASMD) intermediate type. Eur J Paediatr Neurol. 2017 Nov;21(6):907-11. 
18.  Daloze P, Delvin EE, Glorieux FH, Corman JL, Bettez P, Toussi T. Replacement therapy for 
inherited enzyme deficiency: liver orthotopic transplantation in Niemann-Pick disease type A. Am J 
Med Genet. 1977:1(2):229-39. 
Shah AJ, Kapoor N, Crooks GM, Parkman R, Weinberg KI, Wilson K, et al. Successful 
19. 
hematopoietic stem cell transplantation for Niemann-Pick disease type B. Pediatrics. 2005 
Oct;116(4):1022-5. 
Smanik EJ, Tavill AS, Jacobs GH, Schafer IA, Farquhar L, Weber FL Jr, et al. Orthotopic 
20. 
liver transplantation in two adults with Niemann-Pick and her's diseases: implications for the 
treatment of inherited metabolic disease. Hepatology. 1993 Jan;17(1):42-9. 
21.  Kayler LK, Merion RM, Lee S, Sung RS, Punch JD, Rudich SM, et al. Long-term survival 
after liver transplantation in children with metabolic disorders. Pediatr Transplant. 2002 
Aug;6(4):295-300. 
Bayever E, Kamani N, Ferreira P, Machin GA, Yudkoff M, Conard K, et al. Bone marrow 
22. 
transplantation for Niemann-Pick type 1A disease. J Inherit Metab Dis. 1992;15(6):919-28. 
23.  Vellodi A, Hobbs JR, O'Donnell NM, Coulter BS, Hugh-Jones K. Treatment of Niemann-
Pick disease type B by allogenic bone marrow transplantation. Br Med J (Clin Res Ed). 1987 Nov 
28;295(6610):1375-6. 
Schneiderman J, Thormann K, Kletzel M. Niemann-Pick type B: Successful allogeneic 
24. 
hematopoietic stem cell transplantation with correction of enzyme levels -Biology of Blood and 
Marrow Transplantation. ASTCT J. 2005 Feb 01:11(2):81. 
Cassiman D, Packman S, Bembi B, Turkia HB, Al-Sayed M, Schiff M, et al. Cause of death 
25. 
in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency 
(Niemann-Pick disease type B and B variant): Literature review and report of new cases [published 
correction appears in Mol Genet Metab. 2018 Dec;125(4):360]. Mol Genet Metab. 
2016;118(3):206-13. 
26.  McGovern MM, Wasserstein MP, Giugliani R, Bembi B, Vanier MT, Mengel E, et al. A 
prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. 
Pediatrics. 2008 Aug;122(2):e341-9. 
 
27. 
von Ranke FM, Pereira Freitas HM, Mançano AD, Rodrigues RS, Hochhegger B, 
Escuissato D, et al. Pulmonary Involvement in Niemann-Pick Disease: A State-of-the-Art Review. 
Lung. 2016 Aug;194(4):511-8. 
28.  Mendelson DS, Wasserstein MP, Desnick RJ, Glass R, Simpson W, Skloot G, et al. Type B 
Niemann-Pick disease: findings at chest radiography, thin-section CT, and pulmonary function 
testing. Radiology. 2006 Jan;238(1):339-45. 
29.  Wittmann J, Karg E, Turi S, Legnini E, Wittmann G, Giese AK, et al. Newborn screening 
for lysosomal storage disorders in hungary. JIMD Rep. 2012;6:117-25. 
Pavlu-Pereira H, Asfaw B, Poupctova H, Ledvinova J, Sikora J, Vanier MT, et al. Acid 
30. 
sphingomyelinase deficiency. Phenotype variability with prevalence of intermediate phenotype in a 
series of twenty-five Czech and Slovak patients. A multi-approach study. J Inherit Metab Dis. 
2005;28(2):203-27. 
Lidove O, Belmatoug N, Froissart R, Lavigne C, Durieu I, Mazodier K, et al. Deficit en 
31. 
sphingomyelinase acide (maladie de Niemann-Pick B) : une etude retrospective multicentrique de 
28 patients adultes Acid sphingomyelinase deficiency (Niemann-Pick disease type B) in adulthood: 
A retrospective multicentric study of 28 adult cases. La Revue de Médecine Interne. 2017 
May;38(5):291-9. 
32.  Miranda SR, He X, Simonaro CM, Gatt S, Dagan A, Desnick RJ, et al. Infusion of 
recombinant human acid sphingomyelinase into niemann-pick disease mice leads to visceral, but 
not neurological, correction of the pathophysiology. FASEB J. 2000 Oct;14(13):1988-95. 
33.  Horinouchi K, Erlich S, Perl DP, Ferlinz K, Bisgaier CL, Sandhoff K, et al. Acid 
sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat Genet. 
1995 Jul;10(3):288-93. 
34.  Kornhuber J, Tripal P, Reichel M, Muhle C, Rhein C, Muehlbacher M, et al. Functional 
Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with 
broad clinical applications. Cell Physiol Biochem. 2010;26(1):9-20. 
35.  Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, et al. Identification of 
new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation 
model. J Med Chem. 2008 Jan 24;51(2):219-37. 
Immunogenicity Testing of Therapeutic Protein Products ‑ Developing and Validating 
36. 
Assays for Anti-Drug Antibody Detection [Internet]. Rockville: Food and Drug Administration; 
2019 Feb [cited 2021 Sep 15]. Available from: https://www.fda.gov/regulatory-information/search-
fda-guidance-documents/immunogenicity-testing-therapeutic-protein-products-developing-and-
validating-assays-anti-drug 
Limaye S, Steele RH, Quin J, Cleland B. An allergic reaction to erythropoietin secondary to 
37. 
polysorbate hypersensitivity. J Allergy Clin Immunol. 2002 Sep;110(3):530.  
 
RISK MANAGEMENT PLAN - PART VII: ANNEXES  
 
 
ANNEX 4
SPECIFIC ADVERSE DRUG REACTION
FOLLOW-UP FORMS
NOT APPLICABLE
 
ANNEX 6
DETAILS OF PROPOSED ADDITIONAL RISK
MINIMISATION ACTIVITIES
 
Key messages of the additional risk minimization measures 
Prior to the launch of XENPOZYME in each member state the marketing authorization holder 
(MAH) must agree about the content and format of the educational programme, including 
communication media, distribution modalities, and any other aspects of the program, with the 
National Competent Authority. 
The educational program is aimed at minimizing specific safety concerns. 
The MAH shall ensure that in each Member State where XENPOZYME is marketed, all healthcare 
professionals (HCP) and patients/caregivers who are expected to prescribe, dispense, use 
XENPOZYME have access to/are provided with the following educational message to be 
disseminated through professional bodies: 
 HCP educational materials 
 Patient/caregiver educational materials 
1.
HCP educational materials: 
1.1  HCP Guide for HCPs in home infusion setting including nurses:
The HCP guide includes the following key elements: 
 On the front page, contact information of the prescribing/treating physician/centre that can 
be reached at any time. 
 Reminder to read the summary of product characteristics (SmPC) prior to initiating 
treatment.  
 To ensure awareness about the risk of immunogenicity, its monitoring and management, the 
guide includes the following: 
- Requirements that the home infusion HCPs/nurses should be trained for emergency 
measures and should have resuscitative equipment ready prior to initiating care. 
-
Information on signs and symptoms of Infusion associated reactions (IARs), severe 
hypersensitivity or anaphylaxis and recommended actions for the management of 
adverse drug reactions (ADRs) if they occur. 
- Reminder to apply only maintenance dose (mg/kg) as prescribed by the 
treating/prescribing physician. 

Instruction to contact the prescribing/treating physician if the patient experienced signs/ 
symptoms of IARs, hypersensitivity, anaphylaxis or if one or more infusions are missed or 
delayed.  
 Medical evaluation of the patient prior to administration of the infusion at home. 
 
 Requirements and organization of the home infusion including equipment, pre-treatment 
and emergency treatments.  
 Details and instructions on the preparation, reconstitution, dilution and administration of the 
product to prevent the risk of medication errors. A calculation template to prepare the 
infusion solution based on prescribed maintenance dose and patient’s body weight with 
instructions to record the calculation and infusion date. 
 The calculation template can be used as a basis for recording infusion details in the patient’s 
medical record.  
 Reminder to check if additional supplies are required.  
2.
Patient educational materials:
2.1  Patient Card for patients/caregivers
The patient card includes the following elements: 

Instruction to the patients/caregivers to seek urgent medical attention if any signs and 
symptoms of IARs, severe hypersensitivity or anaphylaxis listed in the card appear or 
worsen during and after infusion and to report the event to the treating/prescribing 
physician. 
 Contact information of the prescribing/treating physician/centre that can be reached at any 
time. 
 Reminder to the women of childbearing potential (WOCBP) to discuss with the 
prescribing/treating physician the need for effective contraceptive measures during 
treatment and for 14 days after the last dose if XENPOZYME is discontinued. 
 Reminder to the WOCBP to contact their prescribing/treating physician if they suspect they 
might be pregnant or plan pregnancy. 
 
